Document:

EX-10.ee

 Exhibit 10ee 
 *Confidential Treatment Requested 
 AMENDMENT TO OTSUKA-BMS
ABILIFY AGREEMENTS 
 THIS AMENDMENT TO OTSUKA-BMS ABILIFY AGREEMENTS (“Amendment”), effective as of
October 29, 2012 (“Amendment Effective Date”), is by and between Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), a corporation organized and existing under the laws of Japan, having a principal place of business at
Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-Ku, Tokyo, 108-8242 Japan, and Bristol-Myers Squibb Company (“BMS”), a corporation organized and existing under the laws of Delaware, having a principal place of business at Route
206 and Province Line Road, Princeton, New Jersey, 08540, USA. Otsuka and BMS shall be referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 

WHEREAS, Otsuka and BMS entered into that certain Restated Development and Commercialization Collaboration Agreement dated
October 23, 2001, and an Amendment No. 1 (dated March 28, 2003), an Amendment No. 2 (dated June 5, 2003), an Amendment No. 3 (dated September 25, 2006), an Amendment No. 4 (dated October 31, 2007), an
Amendment No. 5 (dated April 4, 2009) (“Amendment No. 5”), an Amendment No. 6 (dated June 1, 2010), an Amendment No. 7 (dated October 2011), and an Amendment No. 8 (dated as of January 1,
2012) (“Amendment No. 8”) thereto (such Agreement, as amended by such Amendments, being collectively referred to herein as the “Restated Agreement”); 

WHEREAS, pursuant to Amendment No. 5, the Parties agreed, among other things, to extend the term of the Restated Agreement in the
United States until April [*], 2015 (the “U.S. Term”) and to allocate and share Operational Expenses (as defined in Amendment No. 5) and Net Sales of Product (as such terms are defined in the Restated Agreement) in the United
States in accordance with the applicable percentages set forth in Amendment No. 5; 
 WHEREAS, Otsuka and BMS entered into
that certain U.S. Co-Commercialization Agreement effective as of January 1, 2010, and an Amendment No. 1 to the U.S. Co-Commercialization Agreement effective as of January 1, 2012 (the “Co-Commercialization
Amendment”) (such Agreement, as amended by such Co-Commercialization Amendment, being collectively referred to herein as the “U.S. Co-Commercialization Agreement”); 

WHEREAS, as required by Amendment No. 5, the U.S. Co-Commercialization Agreement sets forth, among other things, the number of MRs
and MSLs (stated as full-time equivalents (FTEs)) required to be deployed by the Parties and the number of PDEs required to be provided by the Parties in the United States through [*]; 

WHEREAS, in part to address transitions of Product sales efforts to Otsuka and minimize disruption to the promotion of the Product caused
by such transitions, the Parties entered into the Co-Commercialization Amendment, pursuant to which BMS agreed (among other things) to deploy more MRs in the United States in 2012 and 2013 than it was required to deploy when the U.S.
Co-Commercialization Agreement was originally executed, and the Parties entered into that 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 

 
certain Europe Commercial Resources Agreement effective as of January 1, 2012 (the “Europe Commercial Resources Agreement”), pursuant to which BMS agreed (among other
things) to deploy sales representatives in the European Union (as defined in the Restated Agreement) through [*]; 
 WHEREAS,
Otsuka and BMS now desire to further amend and supplement certain terms and conditions of the Restated Agreement, the U.S. Co-Commercialization Agreement, the Europe Commercial Resources Agreement and, as applicable, related ancillary agreements
between the Parties and/or their Affiliates; and 
 WHEREAS, Otsuka and BMS desire that all other terms and conditions of the
Restated Agreement, the U.S. Co-Commercialization Agreement, the Europe Commercial Resources Agreement and related ancillary agreements between the Parties and/or their Affiliates remain in full force and effect, except to the extent amended by this
Amendment; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
Otsuka and BMS agree as follows: 
 ARTICLE I  

DEFINITIONS 
 1.1 Capitalized terms in this Amendment shall have the same meaning as those in the Restated Agreement, unless specifically defined otherwise in this Amendment or in the U.S. Co-Commercialization
Agreement. As used throughout this Amendment, the term “European Union” shall have the same meaning as in the Restated Agreement, and, for clarity is defined to include Norway, Switzerland and Iceland, in addition to the member countries
of the European Union. 
 ARTICLE II  
 UNITED STATES PROVISIONS 
 2.1 Termination of BMS MR and
MSL Obligations in the United States. Commencing January 1, 2013, BMS shall have no further obligation under the Restated Agreement or the U.S. Co-Commercialization to deploy MRs to Detail Product (including, without limitation, no
obligation to provide PDEs) in the United States or to deploy MSLs to conduct medical activities relating to Product in the United States. As of January 1, 2013, and for the remainder of the U.S. Term, BMS shall have no obligation to diligently
promote Product in the United States, and the terms and conditions of Sections 2.3(b) and (c), 2.4 through 2.7, 2.11 and 2.12 of the U.S. Co-Commercialization Agreement shall not apply to BMS with respect to the period beginning January 1, 2013
through to the end of the U.S. Term, but BMS shall otherwise continue to support Product in the United States as provided herein. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 2. 

 2.2 Transition of Product Personnel Responsibilities in the United States.

 (a) Upon execution of this Amendment and the execution of a mutually-agreed communications plan, Otsuka shall have the
right (but not the obligation) to offer to interview and to offer to hire all of the MRs, Regional Directors (“RDs”), District Managers (“DMs”) and MSLs in the United States who are employed by BMS and are working
in connection with Product (collectively, “Product Personnel”) for employment by Otsuka as soon as possible. Otsuka shall use commercially reasonable efforts to complete its hiring of Product Personnel on or before December 31,
2012. To the extent legally permissible, BMS shall facilitate Otsuka’s opportunity to commence to interview all Product Personnel by no later than November 1, 2012. BMS shall inform all Product Personnel as soon as reasonably possible of
the opportunity to interview with Otsuka, including at the time BMS extends offers (if BMS does extend offers) to any such Product Personnel to fill other product positions within BMS and, in the event BMS has extended such offers to any Product
Personnel before Otsuka’s offer to interview and announcement of openings, by notifying those Product Personnel to whom BMS has made such offers of the opportunity for such Product Personnel to interview with Otsuka for openings at Otsuka. To
promote an efficient interview process, BMS shall provide to all Product Personnel, in advance of Otsuka’s interviews, a [*] containing the following information: (i) [*] for, (ii) [*], and (iii) [*]. Such Product Personnel shall
have the right, in their discretion, to provide such [*] to Otsuka. Following Otsuka’s hiring of any Product Personnel, Otsuka shall inform BMS of the identity of the hired Product Personnel and, as soon as practicable thereafter, BMS shall
certify in writing to Otsuka that such Product Personnel have received sales certifications with respect to Product and the date(s) of such certifications. Such Product Personnel shall also have the right, in their discretion, to provide a summary
of their individual training records to Otsuka, and BMS shall make such summaries of training records available to such Product Personnel prior to their departure from BMS. 
 (b) Otsuka and BMS shall work closely together to promptly generate and agree upon a communications plan relating to the transition of U.S. Product promotion responsibilities and medical field
activities from BMS to Otsuka and communicating the opportunities for Product Personnel to be interviewed and hired by Otsuka. This communications plan will include access by all Product Personnel to a WebEx to be prepared by Otsuka explaining such
employment opportunities at Otsuka. 
 (c) In order to ensure a smooth and effective transition of Product promotion
responsibilities and medical field activities in the United States, and to minimize disruption to the overall Product sales effort in the United States during the transition of promotion responsibilities and medical field activities from BMS to
Otsuka, BMS shall continue to fulfill all of its existing Product Personnel obligations and Required Resource Commitment under the Restated Agreement and the U.S. Co-Commercialization Agreement, including relating to MRs and PDEs, through
December 31, 2012, except only to the extent of a reduction of Product Personnel (and related PDEs) who are hired by Otsuka or, after having been made aware of the opportunity to interview with Otsuka, voluntarily depart BMS prior to that date.
Without limiting the foregoing, through December 31, 2012, BMS shall use commercially reasonable efforts to continue to deploy the same Product Personnel as the U.S. Co-Commercialization Agreement currently obligates BMS to deploy, solely to
Detail or otherwise work in connection with Product, and no other products, with 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 3. 

 
no layoffs, reassignments or other personnel changes or territory or field revisions, except only to the extent such Product Personnel are hired by Otsuka or, after having been made aware of the
opportunity to interview with Otsuka, voluntarily depart BMS. BMS shall work diligently to minimize disruption to Product promotion and medical field activities and responsibilities in the United States. In the event any Product Personnel, after
having been made aware of the opportunity to interview with Otsuka, are offered and elect to accept other positions within BMS through a competitive bidding process, BMS shall not transfer such Product Personnel to such other positions until on or
after January 1, 2013, and BMS shall use commercially reasonable efforts to ensure that such Product Personnel continue their work in connection with Product through December 31, 2012. 

(d) In recognition of the Parties’ efforts to transition Product Personnel responsibilities to Otsuka as soon as possible
during the fourth quarter of 2012, the remedies specified in Sections 2.8, 2.9, 2.10 and 2.12 of the U.S. Co-Commercialization Agreement shall not apply to either Party with respect to the period beginning October 1, 2012 through to the end of
the U.S. Term. 
 (e) Without limiting Otsuka’s right to offer to interview and offer to hire all Product Personnel
as provided and permitted in Paragraph 2.2(a) above, until [*], neither Party shall recruit, induce or solicit for hire any former Product Personnel employed by the other Party (i.e., Otsuka will not recruit or solicit for hire any former Product
Personnel who have accepted other positions within BMS through a competitive bidding process after being informed of their opportunity to interview with Otsuka, and BMS will not recruit or solicit for hire any former Product Personnel who are hired
by Otsuka). 
 2.3 Transition of U.S. Assumed Functions to Otsuka. 

(a) The collaboration between the Parties shall continue in accordance with the terms of the Restated Agreement, the U.S.
Co-Commercialization Agreement and ancillary Product-related agreements, except as amended hereby. BMS shall continue to fulfill, at its sole expense (except as set forth in Paragraph 2.6 below), all of its existing obligations under the Restated
Agreement and the U.S. Co-Commercialization Agreement relating to Product promotion-related commercial functions and medical affairs functions in the United States, including, without limitation, relating to marketing, promotional compliance, market
access, pricing and advocacy, sales training and medical affairs, but excluding (beginning January 1, 2013) the actual deployment of MRs and MSLs in the United States, subject to Otsuka assuming many of such functions as provided in Paragraph
2.3(b) below. For the avoidance of doubt, BMS shall also continue to fulfill all of its other obligations under the Restated Agreement, the U.S. Co-Commercialization Agreement and Product-related ancillary agreements between the Parties and/or their
Affiliates, including all obligations and functions that are not included in the U.S. Assumed Functions (as defined below), for the period of time as provided in such agreements. 

(b) In addition to the transition of MR and MSL responsibilities to Otsuka in the United States as provided in Paragraph 2.2
above, Otsuka shall assume responsibility and authority for certain other Product-related functions (which BMS is currently obligated to 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 4. 

 
perform) in the United States at different times during 2013 or 2014, at Otsuka’s sole expense. The specific Product-related functions that will be assumed by Otsuka (as provided in this
Paragraph 2.3 and in Paragraph 4.1 below) are set forth in Exhibit A-1 and Exhibit A-2 to this Amendment (as such exhibits may be modified in accordance with Paragraph 2.3(c) below) and shall be referred to herein as “U.S.
Assumed Functions.” Exhibit A-1 and Exhibit A-2 (as such exhibits may be modified in accordance with Paragraph 2.3(c) below) also set forth the anticipated timing of the transition from BMS to Otsuka of responsibility
and authority for such U.S. Assumed Functions. 
 (c) The U.S. Assumed Functions that Otsuka will assume as of
January 1, 2013 are set forth in Exhibit A-1 to this Amendment. Except as set forth on Exhibit A-1, Otsuka may inform the Transition Planning Liaison of BMS on or before November 15, 2012 of any modifications to Exhibit A-1
that Otsuka has decided upon, which may include modifying Exhibit A-1 to add or remove functions that Otsuka will assume and/or to change transition timelines for functions set forth in Exhibit A-1. After November 15, 2012, the
Parties must mutually agree upon any modifications to Exhibit A-1 to this Amendment. The U.S. Assumed Functions that Otsuka contemplates assuming by [*], or later, are set forth in Exhibit A-2 to this Amendment. Otsuka may inform the
Transition Planning Liaison of BMS on or before December 31, 2012 of any modifications to Exhibit A-2 that Otsuka has decided upon, which may include modifying Exhibit A-2 to remove functions that Otsuka will assume, and/or to
delay transition timelines for functions set forth in Exhibit A-2, and/or to accelerate the transition timelines for any functions to a point on or after [*]. The Parties must mutually agree upon any modifications to Exhibit A-2 to
this Amendment (i) after December 31, 2012, or (ii) to add any functions to those on Exhibit A-2 that Otsuka will assume, or (iii) to accelerate the transition timelines for any functions on Exhibit A-2 to a point
prior to [*]. Upon Otsuka’s informing the Transition Planning Liaison of BMS informing BMS of modifications to Exhibit A-1 or Exhibit A-2 within the time period(s) specified above, or in the event that the Parties mutually agree
to modify Exhibit A-1 or Exhibit A-2 at any time, Exhibit A-1 and/or Exhibit A-2 (as applicable) shall be deemed modified. Such modified exhibit(s) shall replace Exhibit A-1 and/or Exhibit A-2 attached to
this Amendment (as applicable) and shall delineate those Product-related functions that will be assumed by Otsuka (U.S. Assumed Functions) and the anticipated timing for transition to Otsuka of the U.S. Assumed Functions (on a function-by-function
basis). 
 (d) In furtherance of a smooth and timely transition to Otsuka of the U.S. Assumed Functions, the Parties
shall discuss and use commercially reasonable efforts to agree upon a detailed transition plan by no later than December 31, 2012. In addition, during the period the Parties are discussing such transition plan, Otsuka or a representative of a
consulting firm being retained by Otsuka, shall have the right to meet with BMS personnel performing various functions that Otsuka is contemplating assuming as provided in this Paragraph 2.3, to help determine necessary capabilities, specific
functions being performed, whether it would be better for Otsuka or BMS to perform certain functions and for how long, and to understand systems, processes, third party services, contracts, relationships, etc., relevant to such functions that Otsuka
is contemplating assuming. BMS shall cooperate with Otsuka in this process, including (as Otsuka and BMS deem appropriate) by establishing transition teams and e-rooms for depositing relevant 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 5. 

 
data, contracts and information. Promptly after the Amendment Effective Date, each Party shall appoint a Transition Planning Liaison to facilitate transition planning and shall inform the other
Party of the person it has appointed. 
 (e) Further to facilitate the smooth and timely transition to Otsuka of the U.S.
Assumed Functions, within [*] after the Amendment Effective Date, the Parties shall form a Transition Committee, which shall be comprised of an equal number of representatives from each Party, each with the requisite experience, seniority and
authority to enable such representative to monitor, coordinate and make decisions on behalf of the Parties with respect to transition issues. The Transition Committee shall be a subcommittee of the JCC. Such Transition Committee shall meet on a
monthly basis in person or by conference call to review, oversee, coordinate, discuss the status of, and facilitate the transition of the U.S. Assumed Functions from BMS to Otsuka, until such time as the transition from BMS to Otsuka of all U.S.
Assumed Functions is completed in accordance with the agreed transition plan. Employees or consultants of either Party who are not members of the Transition Committee may attend meetings of the Transition Committee on an ad hoc basis. In
addition, given the importance of the ongoing collaboration between the Parties and the importance to both Parties of a smooth and timely transition, on a bi-monthly basis (i.e. once every other month) until such time as the transition from BMS to
Otsuka of all U.S. Assumed Functions is completed in accordance with the agreed transition plan, the President of Otsuka and a member of the Senior Management Team of BMS shall meet in person or by telephone to discuss the transition of the U.S.
Assumed Functions from BMS to Otsuka. 
 (f) During the transition of the U.S. Assumed Functions from BMS to Otsuka, BMS
shall transfer or make readily available to Otsuka all commercial, medical and other data, records and information related to Product or such U.S. Assumed Functions, including, without limitation, the data, records and information set forth in
Exhibit B attached to this Amendment. Such transfer shall be on a timely basis, as reasonably requested or as reasonably appropriate to effect the timely transition of the U.S. Assumed Functions from BMS to Otsuka. In addition, BMS shall
cooperate with the transition to Otsuka of the U.S. Assumed Functions by (among other things) offering Otsuka ([*]) reasonable access to and guidance from BMS personnel both prior to and during the transition of various functions and
responsibilities. Following completion of the transition to Otsuka of the various U.S. Assumed Functions, and continuing until the expiration of the U.S. Term, BMS shall continue to provide Otsuka ([*]) with reasonable access to and guidance from
BMS personnel who have experience and knowledge relating to such U.S. Assumed Functions 
 (g) Notwithstanding the
transition to Otsuka of the U.S. Assumed Functions, Otsuka anticipates the possibility that Otsuka may not, at the outset, employ sufficient personnel to perform all such functions prior to completion of the transition. In the event Otsuka may not
be able to employ sufficient personnel to perform any one or more U.S. Assumed Function(s) prior to completion of the transition, Otsuka will, as soon as reasonably practicable (but in any event no later than December 3, 2012), inform BMS of
such personnel shortfall, including the specific U.S. Assumed Function(s) (the “Specified Functions”) and the number of personnel (or full-time equivalents) performing the Specified Functions that Otsuka will not be able to employ
prior to completing the transition; provided that Specified Functions may not include functions that are set 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 6. 

 
forth on Exhibit A-1 and are noted thereon as functions that will be transferred to Otsuka as of January 1, 2013 unless otherwise mutually agreed (i.e. Specified Functions may not include
items on Exhibit A-1 that are asterisked). For example, if Otsuka requires [*] employees to perform certain Product marketing functions and, at the outset, Otsuka will only be able to hire [*] such employees, Otsuka will inform BMS of a shortfall of
[*] Product marketing Specified Functions. From and after the date Otsuka informs BMS of the Specified Functions and the specific shortfall in the number of personnel performing such Specified Functions, BMS shall provide personnel (or full-time
equivalents), equal in number to the shortfall specified by Otsuka, who are knowledgeable and competent to perform the Specified Functions, until the earlier of (i) the date on which Otsuka employs other personnel to perform such Specified
Functions or (ii) December 31, 2013. Otsuka shall reimburse BMS’s direct costs of the BMS personnel (or full-time equivalents) performing the Specified Functions beginning on the date set forth in Exhibit A-1 or Exhibit
A-2 (as applicable) by which the Specified Function(s) being performed by such personnel are scheduled to transfer to Otsuka, until the earlier of the date on which Otsuka employs other personnel to perform such Specified Functions, or [*]. The
Parties shall agree upon a commercially reasonable cost-sharing mechanism for the BMS personnel performing the Specified Functions. 
 2.4 Otsuka’s Deployment of [*] MRs in the United States. 

(a) In accordance with Section 2.11(a) of the U.S. Co-Commercialization Agreement, BMS hereby agrees that Otsuka may deploy
up to [*] MRs “Additional MRs”) to Detail Product to any HCPs appropriate to one or more approved indications of Product (including with a focus on [*]), starting no earlier than the Amendment Effective Date. Otsuka and BMS shall
work together to promptly generate and agree upon a communication plan relating to the deployment of the Additional MRs and the messaging/promotional materials to be used by the Additional MRs. 

(b) As soon as reasonably practical, BMS shall provide the Additional MRs with (i) Product promotional samples across the
tablet dosing range, in quantities reasonably requested by Otsuka, and (ii) Product promotional materials (including package inserts and promotional aids) comparable to those being used by MRs in the United States as of the Amendment Effective
Date; provided that, the costs of any Product promotional samples and Product promotional materials utilized by the Additional MRs will be borne solely by Otsuka. BMS shall provide Product promotional materials for the Additional MRs (as well
as for all of Otsuka’s Product MRs) through [*], or for such longer period as the Parties may mutually agree upon. BMS shall provide the Additional MRs (as well as all of Otsuka’s Product MRs) with Product promotional samples across the
tablet dosing range until the expiration of the U.S. Term and thereafter for so long as BMS continues to manufacture Product under the Restated Agreement and related Product supply agreements. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 7. 

 2.5 Otsuka Freedom to Operate in the United States. 

(a) In recognition of Otsuka’s assumption of the responsibility to deploy all MRs and MSLs for Product in the United States
beginning January 1, 2013, and also to assume multiple other responsibilities and functions previously performed by BMS (the U.S. Assumed Functions), commencing January 1, 2013, Otsuka shall have freedom to operate in the United States
with respect to Commercialization of Product, with no further restrictions or obligations under the Restated Agreement or the U.S. Co-Commercialization Agreement, but subject to Paragraph 2.5(b) and Paragraph 5.1 below. Without limiting the
foregoing, beginning January 1, 2013: the terms and conditions of Sections 2.3(b) and (c), 2.4 through 2.7, 2.11 and 2.12 of the U.S. Co-Commercialization Agreement shall not apply to Otsuka, and the obligations set forth in such Sections shall
fall solely within the discretion of Otsuka; Otsuka shall not have any obligation to diligently promote Product in the United States; and there shall be no restrictions or limitations on Otsuka’s right to (or the manner in which it does so)
promote Product or conduct other Product-related Commercialization activities, either itself or with or through a third party in the United States (except to the extent any such other Product-related Commercialization activities are retained by BMS
as provided in Paragraph 4.2 below). 
 (b) Commencing January 1, 2013, subject to Paragraph 5.1(b) below, Otsuka
shall have sole responsibility and authority for generating the Commercial Plan, Marketing Plan and other plans and budgets related to Commercial Operations in the United States, including plans relating to deployment of MRs and MSLs (including the
Target Call List) and budgets of A&P expenses and other Operational Expenses; provided, however, that the Parties have agreed upon a revised budget for A&P expenses and other shared Operational Expenses for calendar years 2013, 2014
and 2015, which revised budget is attached as Exhibit C to this Amendment (the “Shared Expense Budget”), and which replaces in its entirety Exhibit 1 to the Co-Commercialization Amendment, and Otsuka shall have no
authority to reduce the A&P expenses set forth in the Shared Expense Budget without the written consent of BMS. Otsuka may, however, increase such A&P expenses, in its discretion and at it cost. 

2.6 United States Operational Expenses. 
 (a) Through December 31, 2012, BMS and Otsuka shall share Operational Expenses, including the MR and MSL FTE and indirect costs, A&P, distribution, R&D and other marketing expenses, in
accordance with the Restated Agreement and the U.S. Co-Commercialization Agreement. 
 (b) Commencing January 1,
2013, Otsuka shall bear all Otsuka MR and MSL direct and indirect costs. However, in exchange for Otsuka agreeing to assume MR and MSL responsibilities for the period from January 1, 2013 through [*], BMS shall pay Otsuka’s Affiliate,
Otsuka America Pharmaceutical Inc. (“OAPI”), the total sum of [*] which is equal to the [*] of [*] for the [*] BMS shall remit such sum in cash to OAPI between [*] and [*]. 

(c) Commencing January 1, 2013, and continuing until the expiration of the U.S. Term, notwithstanding the transition to
Otsuka of the U.S. Assumed Functions as provided in 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 8. 

 
Paragraphs 2.3 and 4.1 herein, BMS and Otsuka shall continue to share the following Operational Expenses: distribution, R&D (excluding MSL costs) and other marketing expenses (collectively,
“Other Operational Expenses”) in accordance with the Restated Agreement and the U.S. Co-Commercialization Agreement, up to the amount of such Other Operational Expenses budgeted in the Shared Expense Budget attached as Exhibit
C to this Amendment (or such other mutually agreed upon budgeted amounts). For the avoidance of doubt, “Other Operational Expenses” exclude MR and MSL FTE and indirect costs and A&P expenses. Any Other Operational Expenses that
exceed the budgeted amounts set forth in the Shared Expense Budget attached as Exhibit C to this Amendment (or other mutually agreed budgeted amounts) for any calendar year beginning 2013 shall be borne by Otsuka. For clarity, if actual Other
Operational Expenses incurred in a calendar year beginning 2013 are below the agreed budgeted amounts, BMS shall pay [*] of such actual Other Operational Expenses incurred. 
 (d) Commencing January 1, 2013, and continuing until the expiration of the U.S. Term, BMS and Otsuka shall share A&P expenses (excluding “other marketing expenses” that are
included in Other Operational Expenses) as follows: (a) in calendar year 2013, [*] of all A&P expenses as incurred, up to and including [*], and [*] of all A&P expenses that exceed [*]; (b) in calendar year 2014, [*] of all A&P
expenses as incurred, up to and including [*], and [*] of all A&P expenses that exceed [*] as incurred; and (c) in calendar year 2015, through April [*], 2015, [*] of all A&P expenses as incurred, up to and including [*], and [*] of all
A&P expenses that exceed [*] as incurred. The Parties agree to spend no less than the amount of the budgeted A&P expenses set forth in the Shared Expense Budget attached as Exhibit C to this Amendment (or other mutually agreed
budgeted amounts), except in the event of Generic Sales (as defined in Amendment No. 5), in which event the Parties shall mutually agree on an appropriate reduction of A&P expenses (and cost-sharing percentages associated therewith).

 2.7 Puerto Rico and other U.S. Territories. Solely for purposes of this Article 2 and the transfer of responsibilities
described in this Article 2, the “United States” means the fifty (50) states of the United States of America (and the District of Columbia), but excludes Puerto Rico and all of the other territories and possessions of the United
States. For the avoidance of doubt, as set forth in the Restated Agreement, Puerto Rico and all of the other territories and possessions of the United States remain part of the United States for all other purposes, including for purposes of revenue
sharing under the Restated Agreement. 
 ARTICLE III  

EUROPEAN UNION/REST OF TERRITORY PROVISIONS 
 3.1 European Union Promotion. 
 (a) BMS shall deploy sales
representatives in the European Union through [*] in accordance with the Europe Commercial Resources Agreement, and shall have no obligation to deploy sales representatives in the European Union on or after [*]. In addition, pursuant to the Europe
Commercial Resources Agreement, BMS shall expend certain additional operational expenses in support of the sales representatives deployed by BMS through [*], and Otsuka shall reimburse BMS up to a specified amount of such additional operational
expenses actually 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 9. 

 
expended by BMS, as set forth in the Europe Commercial Resources Agreement. In accordance with the Restated Agreement, Otsuka is currently co-promoting Product in the European Union Co-Promotion
Countries and the Nordic Countries (as defined in Amendment No. 5) (collectively, the “G5/Nordic Countries”). Notwithstanding anything to the contrary in the Restated Agreement, the Europe Commercial Resources Agreement or any
other Product-related agreement between the Parties and/or their Affiliates, from and after the Amendment Effective Date, Otsuka shall have the right to deploy its own and any contract sales organization’s sales representatives to promote
Product in any of the G5/Nordic Countries without restriction, including no limitation on the number of sales representatives deployed; provided that, if Otsuka (itself or using a contract sales organization) deploys sales representatives to
promote Product in any G5/Nordics Country prior to transfer of Local Representative status from BMS to Otsuka (or to a third party designated by Otsuka) in such country, such sales representatives (i.e. sales representatives of Otsuka or such
contract sales organization) must use Product promotional materials approved by BMS or its Affiliates and must comply with reasonable applicable policies of BMS or its Affiliates in such country, until such time as Local Representative status is so
transferred in such country. For clarity, other than a contract sales organization as described above, no third party shall have the right to promote Product in any G5/Nordics Country prior to transfer of Local Representative status from BMS to
Otsuka (or to a third party designated by Otsuka) in such country. 
 (b) At such time as BMS ceases to deploy sales
representatives to actively promote Product in any country in the European Union, on a country-by-country basis following transfer of Local Representative status in such country to Otsuka or a third party designated by Otsuka, Otsuka shall have
unilateral freedom to operate with respect to promotion of Product in each such country, with no further obligations (other than revenue sharing with BMS in accordance with the Restated Agreement) or restrictions (including, without limitation, no
restrictions on Otsuka’s right to promote Product or conduct other Product promotion-related and medical affairs activities, itself or with or through a third party) under the Restated Agreement, the Europe Commercial Resources Agreement or any
other Product-related agreements between the Parties and/or their Affiliates. BMS (or its Affiliates at the European level and/or the country level), Otsuka (or its Affiliates at the European level and/or the country level) and any third party that
will be deploying sales representatives to promote Product in the European Union shall work together to ensure a smooth transition of the sales representatives’ Product promotional efforts, and shall discuss and shall use commercially
reasonable efforts to agree on one or more transition plan(s) to ensure local coordination of transitional efforts. During the transition period, BMS or its Affiliate shall transfer or make readily available to Otsuka or a third party designated by
Otsuka all information and records related to Product promotion in the European Union, including Product promotion-related materials, target call lists, and HCP contact records for all HCPs on the target call lists for calendar years 2010, 2011,
2012 and for the first quarter of 2013. Despite the changes in this Paragraph 3.1, BMS and Otsuka shall continue to share Net Sales in each such country in the European Union in accordance with the Restated Agreement (including the agreed allocation
set forth therein). 
 3.2 Rest of Territory Promotion. At such time as BMS ceases to deploy sales representatives
to actively promote Product in any country in the Rest of Territory, Otsuka shall 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 10.

 
have the right, on a country-by-country basis, to request to promote Product to healthcare professionals in such country(ies), either itself or with or through a third party. Otsuka’s
request shall be subject to the consent of BMS, which shall not be unreasonably withheld or delayed. BMS and Otsuka will discuss the reasonable conditions under which Otsuka or a third party designated by Otsuka may begin promoting Product in each
such country, including any local regulatory or compliance requirements in such country, and BMS policies (which shall be provided to Otsuka) relating to Product promotional activities that must be met (such that BMS would not bear compliance risk).
For each country in the Rest of Territory in which Otsuka requests to promote Product and BMS consents to the same, the Parties (or their Affiliates) and any third party designated by Otsuka shall discuss and use commercially reasonable efforts to
agree upon a plan for transitioning Product promotion responsibilities in such country to Otsuka or a third party designated by Otsuka, including coordinating such promotion with other commercial activities, if any, which shall remain the
responsibility of BMS in such country. During the transition period in each such country, BMS or its Affiliate shall use commercially reasonable efforts to transfer or make readily available to Otsuka or a third party designated by Otsuka all
relevant information and records related to Product promotion in such country in order to facilitate such transition. For clarity, if Otsuka elects to promote in a given country in the Rest of Territory, it will be at Otsuka’s sole expense, and
there will be no change to the sharing of Net Sales in each such country in the Rest of Territory in accordance with the Restated Agreement (including the agreed allocation set forth therein). In addition, the Parties will agree on a process for
communicating Product forecasts for manufacturing purposes. 
 3.3 Other Product-Related Obligations. On a
country-by-country basis in the European Union and the Rest of Territory, where Otsuka (or a third party designee) is promoting Product as provided in Section 3.1 and 3.2 above, the Parties acknowledge that Otsuka (or a third party) may desire
to assume one or more Product-related obligations (in addition to any Product promotion-related activities that Otsuka may assume in accordance with Paragraphs 3.1 and 3.2 above) in such country prior to the expiration of the Restated Agreement,
including regulatory, distribution and/or pharmacovigilance (“PV”) obligations (“Other Product-Related Obligations”), that BMS otherwise is and would be required to continue to perform in accordance with the
Restated Agreement and other applicable Product-related agreements between the Parties and/or their Affiliates, including the Post-Termination Services Agreement. In the event that the Parties mutually agree with respect to Otsuka’s (or such
third party’s) assumption of certain Other Product-Related Obligations, the Parties shall discuss and use commercially reasonable efforts to agree upon a plan to ensure local coordination of the transition from BMS to Otsuka (or such third
party) of such agreed Other Product-Related Obligations, and Otsuka (or such third party) will assume such agreed Other Product-Related Obligations, on a country-by-country basis, as soon as reasonable (provided that any PV activities assumed by
Otsuka or such third party will be limited to collecting safety data information and transferring such information to BMS, unless Otsuka elects to assume global PV responsibilities). 

3.4 Revenue Sharing. Notwithstanding the transition to Otsuka or a third party designated by Otsuka of Product promotion or
some other Product-related functions in any country in the European Union or the Rest of Territory, in accordance with Paragraphs 3.1, 3.2 or 3.3 above, BMS and Otsuka shall continue to share Net Sales in each such country in accordance with the
Restated Agreement (including the agreed allocation set forth therein). 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 11.

 ARTICLE IV  

TERRITORY-WIDE PROVISIONS 
 4.1 Transition of Clinical and Certain Regulatory Functions in the Territory. BMS shall continue to perform clinical and regulatory functions related to Product in the Territory in
accordance with the Restated Agreement. As soon as reasonably practicable for Otsuka (currently contemplated to be by no later than [*]), Otsuka shall assume responsibility and authority for certain clinical and regulatory activities relating to
Product in the United States (excluding PV and CMC regulatory activities), at Otsuka’s sole expense. The Product-related clinical and regulatory activities that Otsuka shall assume in the United States (which are included as part of the U.S.
Assumed Functions) and centralized regulatory activities (i.e. interactions with the EMA) in the European Union, and the anticipated timing for transition of such clinical and regulatory activities to Otsuka, are set forth in Exhibit A-2 to
this Amendment, as Exhibit A-2 may be modified in accordance with Paragraph 2.3(c) above. In the event that Otsuka desires to assume responsibility and authority for clinical and regulatory activities relating to Product in other countries in
the Territory (following transfer of Local Representative status where required), Otsuka shall inform BMS of which Product-related clinical and regulatory activities Otsuka desires to assume outside of the United States, the countries in which
Otsuka desires to assume such activities, and the anticipated timing for Otsuka’s capability to assume such activities. In such event, the Parties shall use commercially reasonable efforts to agree on a plan for the transition of such
Product-related clinical and regulatory functions to be assumed by Otsuka on a country-by-country basis. During the period of such transition planning, and during the implementation of such transition to Otsuka of Product-related clinical and
regulatory activities (in accordance with such agreed transition plan), and until expiration of the Restated Agreement, on a country-by-country basis, BMS shall continue to provide Otsuka (at no cost to Otsuka) with reasonable access to and guidance
from BMS’s (and/or its Affiliates’) personnel who have experience and knowledge relating to such transitioned Product-related clinical and regulatory functions. The Parties agree that nothing herein shall amend Paragraph 3 of Amendment
No. 8, which paragraph shall remain in full force and effect in accordance with its terms. 
 4.2 BMS’s
Continuing Responsibilities. BMS shall continue to be responsible for, and shall perform at its sole expense in accordance with all applicable Product-related agreements between the Parties and/or their Affiliates, all Product-related activities
and functions in the Territory that are not expressly assumed by Otsuka in accordance with Paragraphs 2.3, 3.1(b), 3.3 and 4.1 above, including, without limitation, all Product promotion-related, medical affairs, clinical and regulatory functions in
the United States that are not assumed by and transitioned to Otsuka as set forth in Exhibit A-1 and Exhibit A-2 to this Amendment (as such exhibits may be modified in accordance with Paragraph 2.3(c) above). Without limiting the
foregoing, except for any functions that are assumed by Otsuka or a third party in accordance with Paragraph 3.3 above, BMS shall continue to be responsible for, and shall perform at its sole expense, Product distribution, manufacture, CMC
regulatory and PV activities and responsibilities, in each case, in accordance with the Restated Agreement, the U.S. Co-Commercialization Agreement, the Revised 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 12.

 
Pharmacovigilance Agreement Regarding Aripiprazole between the Parties (effective March 10, 2010, and as subsequently amended), and other applicable Product-related agreements between the
Parties and/or their Affiliates, including the Post-Termination Services Agreement and the Post-Termination Manufacturing and Supply Agreement. 
 4.3 Transfer of Countries to Reserved Territory. Any country in the Territory in which BMS has not yet commenced the sale of Product as of the Amendment Effective Date shall be automatically
and immediately deemed removed from the Territory and transferred to and included in the Reserved Territory as of the Amendment Effective Date. In addition, Vietnam (which, pursuant to Amendment No. 7 to the Restated Agreement, is excluded from
the Territory) shall be automatically and immediately deemed transferred to and included in the Reserved Territory as of the Amendment Effective Date. Upon the Amendment Effective Date, all of BMS’s rights and obligations under the Restated
Agreement shall be deemed terminated with respect to each country transferred to the Reserved Territory in accordance with this Paragraph 4.4, and the provisions of Section 13.1 of the Restated Agreement shall apply to each such country (to the
extent applicable in such country). Without limiting the foregoing, BMS shall have no right to receive any share of Net Sales in any such country or any fee in connection with Net Sales in Vietnam, and BMS shall cooperate with Otsuka in connection
with the transition of rights and responsibilities to Otsuka in each such country that is transferred to the Reserved Territory. Transfer of a country as provided in this Paragraph 4.4 shall not limit or adversely affect any of BMS’s rights
that accrued in such country prior to such removal, nor release BMS from any liability or obligation that accrued prior to such removal. 
 4.4 Post-Termination Services in the United States. The Parties entered into that certain Abilify Post-Termination Services Agreement dated as of April 4, 2009, pursuant to which BMS is
obligated to perform Post-Termination Services (as defined in the Post-Termination Services Agreement), including Product distribution and PV services, following expiration or termination of the Restated Agreement on a Region-by-Region (as defined
in the Post-Termination Services Agreement) or country-by-country basis. With respect to Post-Termination Services in the United States, Otsuka is contemplating assuming responsibility for all such Post-Termination Services except for Product
distribution in the United States, prior to or at the expiration of the U.S. Term. As soon as reasonably practicable after the Amendment Effective Date, the Parties shall discuss in good faith, without any obligation to enter into an agreement, an
amendment to the Post-Termination Services Agreement pursuant to which (i) Otsuka could assume all Post-Termination Services in the United States except for Product distribution; (ii) BMS would have no obligation after the U.S. Term to
perform any Post-Termination Services in the United States except for Product distribution; and (iii) the Parties would mutually agree on a fee to be paid by Otsuka to BMS for BMS to perform Product distribution services in the United States
after the U.S. Term. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 13.

 ARTICLE V  

COMMITTEE PROVISIONS 
 5.1 PDC and JCC. 
 (a) Beginning (i) January 1,
2013, with respect to the United States and (ii) [*], with respect to the European Union, an Otsuka representative will be the sole Chair of the JCC and the PDC, and there shall be no Co-Chair of those committees. Beginning January 1,
2013, subject to Subparagraphs 5.1(b)(i) and (ii) below, Otsuka shall have final decision-making authority on all JCC matters relating to the Commercialization of Products (but not distribution, manufacturing, delivery, supply and packaging,
which functions remain under the operational responsibility of BMS) and all PDC matters with respect to the United States, including, without limitation, Product pricing, discounting and key messaging. Beginning [*], Otsuka shall have final
decision-making authority on all JCC matters relating to the Commercialization of Products (but not distribution, manufacturing, delivery, supply and packaging, which functions remain under the operational responsibility of BMS) with respect to the
European Union, except with respect to Product pricing, discounting and key messaging. Product pricing, discounting and key messaging in the European Union shall be determined by mutual agreement of the Parties, subject to applicable laws and
regulations, and further, with respect to key messaging, subject to Subparagraph 5.1(b)(iii) below. Notwithstanding the above provisions, neither the Otsuka Chair, the JCC, the PDC, nor any plan approved by the JCC may impose additional expenses or
obligations on BMS or its Affiliates beyond those specified in the Restated Agreement, the Shared Expense Budget or the Europe Commercial Resources Agreement, without the written consent of BMS. Further, at JCC meetings, Otsuka will be required to
discuss, and shall give BMS an opportunity to provide input regarding, the status of Product Commercialization activities in the United States and the European Union, including performance updates, forecasting information pertinent to BMS’s
manufacturing obligations, and other information pertaining to BMS’s ongoing obligations related to Product Commercialization in the United States and the European Union. In addition, the JCC shall oversee the progress of the transition and the
work of the Transition Committee. 
 (b) Notwithstanding Paragraph 5.1(a) above, Otsuka’s final decision-making
authority with respect to JCC matters in the United States shall be subject to the provisions of subparagraphs (i) and (ii) below; provided that, subject to such provisions, Product pricing and discounting decisions in the United States in
2013, 2014 and 2015 are within Otsuka’s sole discretion. Decisions regarding Product key messaging in the European Union shall be subject to subparagraph (iii) below. 

(i) Commencing January 1, 2013, and continuing until [*], BMS and Otsuka shall share Discretionary Payer Discounts (as
defined below), up to [*] in 2013 and up to [*] in 2014, in proportion to the Parties’ existing revenue tier splits as set forth in Amendment No 5. As used herein, the term “Discretionary Payer Discounts” means discounts
provided to commercial, Medicare (Part D) and Medicaid (supplemental rebate) payers to maintain or improve formulary access. Discretionary Payer Discounts excludes co-pay programs and non-discretionary discounts such as FSS, PHS, Medicaid (CPI
Penalty, ADAP, SDAP) and Medicare (coverage gap). In the event that Otsuka, without the consent of BMS, grants any Discretionary Payer Discounts in excess of [*] in 2013 and/or [*] in 2014 (“Excess Discounts”), the Excess Discounts
shall be added to Net Sales at the end of 2013 and/or 2014, respectively (the sum of the actual Net Sales and the Excess Discounts will be referred to herein as “Adjusted Net Sales”), and the Parties shall calculate the following:
(A) the amount of BMS’s share of actual Net 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 14.

 
Sales (after deducting from Product gross sales all discounts, including Excess Discounts) utilizing the existing revenue sharing tiers set forth in Amendment No 5, (B) the amount of
BMS’s share of Adjusted Net Sales utilizing the existing revenue sharing tiers set forth in Amendment No 5, and (C) the difference between the amounts calculated in accordance with clauses (A) and (B). After completing such
calculations, the amount of the difference calculated in accordance with clause (C) in the preceding sentence will be received by BMS as an increase in its share of Net Sales in the United States for the year in question; provided that,
if actual Net Sales exceed [*] in 2013 and/or [*] in 2014, the preceding adjustment mechanism shall no longer apply and BMS shall not be entitled to receive any such difference. The timing of the calculation and settlement will be addressed based on
the Parties’ existing revenue settlement process. If Otsuka grants Discretionary Payer Discounts that exceed the Excess Discounts threshold(s) above [*] in 2013 and/or [*] in 2014), and if BMS consents to such increased Discretionary Payer
Discounts in the interest of Product Commercialization, then the Excess Discounts threshold(s) above shall be increased, and the calculations set forth above shall be adjusted, accordingly. Examples of the calculations under this Subparagraph
5.1(b)(i) are set forth in Exhibit D attached to this Amendment. 
 (ii) All Product pricing decisions in the
United States for 2013, 2014 and 2015 are within Otsuka’s sole discretion. However, subject to applicable laws and regulations, if: (1) commencing January 1, 2013, and continuing until [*], Otsuka decides to increase the wholesale
list price (WLP) of Product in the United States to a WLP that is less than [*] on an annual weighted-average basis, above the WLP in effect as of October 1, 2012;or (2) commencing [*], and continuing until [*], Otsuka decides to increase
the wholesale list price (WLP) of Product in the United States to a WLP that is less than [*], on an annual weighted-average basis, above the WLP in effect as of [*]; and, (3) in either case, (1) or (2), BMS does not consent to the lower
price percentage increase(s) that Otsuka decided to implement; then (4) the Parties shall calculate the following: (A) the amount of Net Sales that would have been achieved in the year in question if Otsuka had increased the price at least
by the percentage stated above (the “Predicted Net Sales”), calculated as set forth below; (B) the amount of BMS’s share of actual Net Sales utilizing the existing revenue sharing tiers set forth in Amendment No 5;
(C) the amount of BMS’s share of Predicted Net Sales utilizing the existing revenue sharing tiers set forth in Amendment No 5; and (D) the difference between the amounts calculated in accordance with clauses (B) and (C). After
completing such calculations, the amount of the difference calculated in accordance with clause (D) in the preceding sentence will be received by BMS as an increase in its share of Net Sales in the United States for the year in question;
provided that, if Net Sales are in excess of [*] in 2013 and/or [*] in 2014, BMS shall not be entitled to receive any such difference. The timing of the calculation and settlement will be addressed based on the Parties’ existing revenue
settlement process. If Otsuka decides to increase the WLP in 2013 or 2014 by less than the percentages set forth above, and if BMS consents to such lower percentage increases in the interest of Product Commercialization, then the above formula shall
not be implemented and BMS shall receive no additional share of Net Sales as provided above. The Parties agree that any increase of the WLP to be effective on or about January 1, 2013, shall not be greater than [*] above the WLP in effect as of
October 1, 2012. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 15.

 For purposes of this Subparagraph 5.1(b)(ii), the Parties shall calculate Predicted Net Sales as follows:
(x) the Parties shall determine the difference between the above price percentage for a given year (i.e. [*] for 2013 and [*] for 2014) and the actual price percentage increase that Otsuka decided to implement in such year (on an annual
weighted-average basis); (y) the Parties will multiply (I) the sum of (A) [*] plus (B) [*] and (z) [*]. For example, if Otsuka decided to implement a [*] price increase (on an annual weighted-average basis) in 2013, the
Parties would multiply the [*] in 2013 by [*] to arrive at the [*], and the Parties would deduct the [*] from such [*] to arrive at [*]. 
 (iii) As of the Amendment Effective Date, the Parties are promoting Product, on a limited basis, for the [*] in the European Union (in addition to the [*]). The Parties hereby agree to an expanded
right for Otsuka, its Affiliates and third parties designated by Otsuka to promote Product for the [*] in the European Union as follows: 
 (A) By no later than [*], Otsuka will provide to BMS (through the Europe Alliance Committee) a business plan relating to the promotion of Product for the [*] in the European Union. Such plan shall
include, without limitation: (1) the anticipated timing for commencing the promotion of Product for the [*] in the European Union, on a country-by-country basis; (2) which entity (Otsuka, its Affiliates or a third party designated by
Otsuka) will promote Product for the [*], on a country-by-country basis; (3) key messaging; (4) target audience; (5) financial forecasts and supporting market research; (6) customer segmentation; and (7) relative support
between the [*] and [*] (such business plan, the [*]). BMS shall have the right to provide comments and feedback on such plan within a reasonable time after BMS receives the [*]. Otsuka shall consider in good faith all reasonable comments and
feedback from BMS. 
 (B) In the event Otsuka wishes to expand its existing rights, as of the Amendment Effective Date, to
promote Product (itself or through its Affiliate or a third party in accordance with Paragraph 3.1 above) for the [*] in the European Union at any time from [*] through [*], Otsuka shall obtain the written consent of BMS or its Affiliate, which
consent BMS or its Affiliate shall not unreasonably withhold or delay, and may grant at any Europe Alliance meeting or otherwise. 
 (C) On and after [*], with or without the consent of BMS or its Affiliates, Otsuka, its Affiliates and any third party designated by Otsuka (in accordance with Paragraph 3.1 above) may promote Product for
the [*] in the European Union using key messaging for [*] as Otsuka deems appropriate, subject to applicable laws and regulations; provided that, if Otsuka fails to provide BMS with a [*] with respect to a country in the European Union at [*] prior
to [*], Otsuka (and/or its Affiliates and any third party designated by Otsuka) may only commence promotion of Product for the [*] in such country [*] after Otsuka has provided a [*] with respect to such country to BMS, during which period, BMS may
provide comments and feedback on such [*] to Otsuka, which Otsuka shall consider in good faith. The Parties contemplate that Otsuka will have provided the [*] to BMS on or before [*], but this proviso addresses the unanticipated event that Otsuka
delays doing so. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 16.

 (D) In the event sales representatives of Otsuka, its Affiliate or any third party promote
both Product and some other product simultaneously, such sales representatives shall not promote with negative messaging against Product during the term of the Restated Agreement in the European Union. 

(E) For the avoidance of doubt, BMS and Otsuka shall continue to share Net Sales in the European Union in accordance with the Restated
Agreement (including the agreed allocation set forth therein). Further for the avoidance of doubt, the above rights of Otsuka are in addition to, and not in limitation of, Otsuka’s existing rights, as of the Amendment Effective Date, to promote
Product in the European Union. 
 (c) There shall be no change to JCC or PDC decision-making authority in the Rest of
Territory, and the terms of Section 5.1 of the Restated Agreement shall continue to apply to JCC responsibilities, governance and decision-making with respect to each country in the Rest of Territory during the term of the Restated Agreement.
Notwithstanding the foregoing, in those countries in the Rest of Territory in which Otsuka requests to promote Product and BMS consents to the same in accordance with Paragraph 3.2 above, after BMS ceases to deploy sales representatives to actively
promote Product in such countries, committee decision-making with respect to such countries shall be the same as the committee decision-making with respect to the European Union on and after [*], as set forth in Paragraph 5(a) and Subparagraph
5(b)(iii) above, mutatis mutandis, and neither the Otsuka Chair, the JCC, the PDC, nor any plan approved by the JCC may impose additional expenses or obligations on BMS or its Affiliates without the written consent of BMS. 

(d) To preserve the status quo, beginning on October 25, 2012, and continuing until December 31, 2012, with respect to
all JCC matters in the United States relating to the Commercialization of Products (but not distribution, manufacturing, delivery, supply and packaging, which functions remain under the operational responsibility of BMS) and all PDC matters in the
United States, and beginning on October 25, 2012, and continuing until [*], with respect to all JCC matters in the European Union relating to the Commercialization of Products (but not distribution, manufacturing, delivery, supply and
packaging, which functions remain under the operational responsibility of BMS), Otsuka and BMS shall have equal decision-making authority on all such JCC and PDC matters, and neither Party nor its Chair or Co-Chair of either such committee shall
have tie-breaking authority with respect to any such United States or European Union matters. In the event the JCC or the PDC Chair and Co-Chair are unable to reach agreement on any such JCC or PDC United States or European Union matters during the
applicable time period specified above, the unresolved matter shall be referred to and resolved as soon as reasonably possible by the President of Otsuka and the President, U.S. Pharmaceuticals, of BMS (or a designee thereof). 

ARTICLE VI 

MISCELLANEOUS PROVISIONS 
 6.1 Amendment. The Restated Agreement, the U.S. Co-Commercialization Agreement, the Europe Commercial Resources Agreement and any ancillary Product-related

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 17.

 
agreements between the Parties and/or their Affiliates are hereby deemed amended to the extent necessary to give full effect to the provisions of this Amendment; provided that Paragraphs 4 and 5
of Amendment No. 8 shall survive in accordance with its terms notwithstanding anything herein to the contrary. 
 6.2
Governing Terms. Except as modified herein, the Restated Agreement, the U.S. Co-Commercialization Agreement, the Europe Commercial Resources Agreement and any ancillary Product-related agreements between the Parties and/or their
Affiliates shall remain in full force and effect in accordance with their terms, as previously amended. For the avoidance of doubt, nothing herein shall limit or modify any transfer or transition terms of the Restated Agreement, the U.S.
Co-Commercialization Agreement or any ancillary Product-related agreements between the Parties and/or their Affiliates, including, without limitation, Sections 4.5.2, 4.5.3, 4.5.5, 12.7 and Article 13 of the Restated Agreement and Paragraph 6 the
Post-Termination Services Agreement, all of which shall remain in full force and effect. To the extent that there are any inconsistencies between this Amendment and the Restated Agreement, the U.S. Co-Commercialization Agreement, the Europe
Commercial Resources Agreement, or any ancillary Product-related agreements between the Parties and/or their Affiliates, the terms of this Amendment shall supersede the Restated Agreement, the U.S. Co-Commercialization Agreement, the Europe
Commercial Resources Agreement, or such ancillary agreements, as applicable. 
 6.3 Counterparts; Electronic
Signature. This Amendment may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Each Party may execute this Amendment by facsimile transmission or in
AdobeTM Portable Document Format (PDF) sent by electronic mail. Facsimile or PDF signatures of authorized signatories of the Parties will be deemed to be original signatures, will be valid and binding, and, upon delivery, will constitute due
execution of this Agreement. 
 [Signature Page Follows] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 18.

 IN WITNESS WHEREOF, Otsuka and BMS agree that this Amendment is effective as of the
Amendment Effective Date set forth above. 
  

									
	OTSUKA PHARMACEUTICAL CO., LTD.	  		  	BRISTOL-MYERS SQUIBB COMPANY
					
	By: 	  	 /s/ Taro Iwamoto, Ph.D.
	  		  	By:	  	 /s/ Giovanni Caforio

		  	(Signature)	  		  		  	(Signature)
					
	Name:	  	Taro Iwamoto, Ph.D.	  		  	Name:	  	Giovanni Caforio
					
	Title:	  	President and Representative Director	  		  	Title:	  	President, U.S. Pharmaceuticals
					
	By:	  	 /s/ Tetsuya, Tachikawa
	  		  		  	
		  	(Signature)	  		  		  	
					
	Name:	  	Tetsuya, Tachikawa, Ph,D.	  		  		  	
					
	Title:	  	Operating Officer, Licensing	  		  		  	

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 19.

 EXHIBIT A-1 
 FUNCTIONS TO BE TRANSITIONED TO OTSUKA BY JANUARY 1, 2013 
 The following
United States functions and activities (“U.S. Assumed Functions”) shall be assumed by Otsuka and transitioned from BMS to Otsuka by January 1, 2013, all in accordance with and subject to the terms and conditions of this
Amendment, of which this Exhibit A-1 is a part (subject to modification in accordance with Paragraph 2.3(c)): 
 [*] [CONTENT REDACTED]

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 20.

 EXHIBIT A-2 
 FUNCTIONS TO BE TRANSITIONED TO OTSUKA BY APRIL [*], 2013 OR LATER IN 2013 

The following United States functions and activities (“U.S. Assumed Functions”) shall be assumed by Otsuka and
transitioned from BMS to Otsuka by April [*], 2013 or later in 2013 or 2014 (by the dates set forth below), all in accordance with and subject to the terms and conditions of this Amendment, of which this Exhibit A-2 is a part (subject to
modification in accordance with Paragraph 2.3(c)): 
 [*] [CONTENT REDACTED] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 21.

 EXHIBIT B 
 DATA, RECORDS AND INFORMATION 
 The following is a list of data, records
and information related to Product or related to U.S. Assumed Functions. The following list is illustrative of such data, records and information that BMS must transfer or make available to Otsuka in accordance with Paragraph 2.3(f) and Paragraph
4.1 of this Amendment, and is not intended to limit the Product-related data, records and information that BMS must transfer or make available to Otsuka. The Parties acknowledge that in order to ensure a smooth transition of responsibilities to
Otsuka, the Parties shall mutually agree upon the scope and method of the transfer of the following materials, taking into account whether such materials exist, whether Otsuka already possesses such information, whether such materials contain
information of BMS that relates to products other than Product (in which case such information shall be redacted or otherwise segregated), whether such materials contain material that is governed by third-party agreements, compliance with applicable
law (e.g. privacy), and whether physical transfer of such records (as opposed to maintenance by BMS in accordance with its record retention policies, with Otsuka having access to such information upon reasonable request) is necessary or desirable.
The Parties also acknowledge that the following list may not be exhaustive. 
 [*][CONTENT REDACTED] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 22.

 EXHIBIT C 
 SHARED EXPENSE BUDGET 
  

							
	 Other Operational Expenses
	  	2013	  	2014	  	2015
				
	 Distribution
	  		  		  	
	 Other Marketing
	  		  		  	
	 R&D
	  		  		  	
	 Total Other Operational Expenses
	  		  		  	
				
	 Cost Share % (BMS/Otsuka)
	  		  		  	
				
	 Advertising & Promotion
	  	 	  	 	  	 
				
	 Cost Share $ (BMS/Otsuka)
	  		  		  	

 Notes: 
 “Other Marketing” includes [*] 
 R&D includes [*] 

[*] 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 23.

 EXHIBIT D 
 EXAMPLES FOR SUBPARAGRAPH 5(b)(i) RELATING TO EXCESS DISCOUNTS 
 This
Exhibit sets forth hypothetical examples of the treatment of Excess Discounts as described in Subparagraph 5.1(b)(i) of this Amendment. 
 Example 1 (Hypothetical Scenario) 
 If: 

 

	 	•	 	 The total amount of Discretionary Payer Discounts (as defined in Subparagraph 5.1(b)(i)) in 2013 is [*] 

 

	 	•	 	 The Excess Discounts (as defined in Subparagraph 5.1(b)(i)) in 2013 is [*] (i.e. [*] – [*]) 

 

	 	•	 	 The actual Net Sales of Product in 2013, after deducting from gross sales all Discretionary Payer Discounts, including the Excess Discounts [*] and
other deductions from gross sales pursuant to the Restated Agreement, is [*] 

 then, 

 

	 	•	 	 The Adjusted Net Sales (as defined in Subparagraph 5.1(b)(i)) is [*] (i.e. [*] + [*] of Excess Discounts); 

 

	 	•	 	 The amount of BMS’s share of actual Net Sales, utilizing the existing revenue sharing tiers set forth in Amendment No. 5, is [*] (see chart
below); 

  

	 	•	 	 The amount of BMS’s share of Adjusted Net Sales, utilizing the existing revenue sharing tiers set forth in Amendment No. 5, is [*] (see chart
below); and 

  

	 	•	 	 The amount of the difference received by BMS as an increase in its share of Net Sales in the United States, as provided in clause (C) of
Subparagraph 5(b)(i), is [*] (i.e., [*]) 

  

															
	 Annual
Net Sales Tiers ($M)
	  	% of Net Sales
in Tier to BMS	 	 	BMS’s share of
Actual Net Sales	 	  	BMS’s share of
Adjusted Net Sales	 
	    $0
	  	$2,700	  	 	50	% 	 	 	[*]	  	  	 	[*]	  
	    $2,700
	  	$3,200	  	 	20	% 	 				  			
	    $3,200
	  	$3,700	  	 	7	% 	 				  			
	    $3,700
	  	$4,000	  	 	2	% 	 				  			
	    $4,000
	  	$4,200	  	 	1	% 	 				  			
	 > $4,200
	  		  	 	20	% 	 				  			
		  		  				 	  
	  
	 	  	  
	  
	 
	 Total
	  		  				 	 	[*]	  	  	 	[*]	  

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 24.

 Example 2 (Hypothetical Scenario) 

If: 
  

	 	•	 	 The actual total amount of Discretionary Payer Discounts (as defined in Subparagraph 5.1(b)(i)) in 2013 is [*] 

 

	 	•	 	 The Excess Discounts (as defined in Subparagraph 5.1(b)(i)) in 2013 is [*] (i.e. [*] – [*]) 

 

	 	•	 	 The actual Net Sales of Product in 2013, after deducting from gross sales all Discretionary Payer Discounts, including the Excess Discounts ([*]) and
other deductions from gross sales pursuant to the Restated Agreement, is [*] 

 then, 

Because actual Net Sales exceed [*], the Parties will not calculate Adjusted Net Sales or make the other calculations set forth in
Subparagraph 5.1(b)(i) and BMS will not retain any difference pursuant to clause (C) of Subparagraph 5(b)(i), notwithstanding that the Excess Discounts is [*] [*] in 2013. 

  
 *CONFIDENTIAL
TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION 
 25.EX-10.oo

 Exhibit 10oo 

 
 

 
 PERFORMANCE SHARE UNITS AGREEMENT 

Under the Bristol-Myers Squibb Company 
 2012 Stock Award and Incentive Plan 
 2013-2015 Performance Share Units Award

 Bristol-Myers Squibb Company (the “Company”) has granted you a Performance Share Units Award as set forth in the Grant Summary.
This award is subject in all respects to the terms, definitions and provisions of the 2012 Stock Award and Incentive Plan (the “Plan”) adopted by the Company. 
 Award Date: 
 Performance Cycle Start Date: January 1, 2013 

Please refer to the Grant Summary for the Target Number of Performance Share Units relating to the 2013-2015 performance cycle:

 2013 Performance Share Units (13-15 Cycle): One-third of total award 

2014 Performance Share Units (13-15 Cycle): One-third of total award 

2015 Performance Share Units (13-15 Cycle): One-third of total award 

The year referenced for each of these three “tranches” is the “Performance Year” for that tranche. 

The range at which Performance Share Units may be earned for varying performance will be set for each tranche by March 30 of the
Performance Year. The range for the 2013 Performance Share Units is included on Exhibit A attached hereto. 
 Minimum Performance
Condition: If you have been designated a Covered Employee (as defined in the Plan) for a Performance Year, then a required condition in order for you to earn Performance Share Units for the Performance Year will be that the Minimum Performance
Condition has been achieved (in addition to achievement of the Performance Goals). A separate Minimum Performance Condition will be set for each tranche by March 30 of the Performance Year. The Minimum Performance Condition for the 2013
Performance Share Units is included on Exhibit A attached hereto. 
 Performance Goal and Earning Date: A separate Performance
Goal will be set for each tranche by March 30 of the Performance Year, specifying the number of Performance Share Units that may be earned for specified levels of performance. The Earning Date will be December 31 of the Performance Year.
The Performance Goals for the 2013 Performance Share Units are included on Exhibit A attached hereto. 
 Vesting: Earned
Performance Share Units will vest on March 10, 2016, subject to earlier vesting at the times indicated in Sections 6 (including in connection with certain terminations following a Change in Control) and 8. 

Settlement: Earned and vested Performance Share Units will be settled by delivery of one share of the Company’s Common Stock, $0.10
par value per share (“Shares”), for each Performance Share Unit being settled. Dividend equivalents will accrue and be payable in connection with Performance Share Units at the time and to the extent that the underlying Performance Share
Unit becomes payable. Settlement shall occur at the time specified in Section 4 hereof. 

  
 1 

 1. PERFORMANCE SHARE UNITS AWARD 

The Compensation and Management Development Committee of the Board of Directors of Bristol-Myers Squibb Company (the
“Committee”) has granted to you the opportunity to earn the 2013 Performance Share Units as designated herein subject to the terms, conditions and restrictions set forth in this Agreement. In addition, the Committee hereby indicates its
intention to grant to you the opportunity to earn the 2014 Performance Share Units and the 2015 Performance Share Units for the 2013-2015 performance cycle and subject to this Agreement; such grants shall become effective only at such time as the
Committee has specified the Minimum Performance Condition (if the Minimum Performance Condition is applicable to you) and the Performance Goal for those Performance Share Units (by March 30 of the relevant Performance Year), except as otherwise
provided in this Section 1 and in Sections 6(a) and 6(b). The target number of each tranche of Performance Share Units and the kind of shares deliverable in settlement, the calculation of earnings per share as a Performance Goal, and other
terms and conditions of the Performance Share Units are subject to adjustment in accordance with Section 11 hereof and Plan Section 11(c). In the event of a Change in Control, you will become legally entitled to have the grant of
Performance Share Units specified hereunder become effective (i) for the Performance Year in effect at the date of the Change in Control, at the time of the Change in Control (if the grant was not previously effective) if you were employed by
the Company or a subsidiary or affiliate immediately before the Change in Control, and (ii) for any Performance Year beginning after the year in which the Change in Control occurred, at the beginning of such Performance Year if you remain so
employed at that time. In each case relating to Performance Share Units the grant of which is effective at or following a Change in Control, the Minimum Performance Condition and the Performance Goal for such Performance Share Units shall be
reasonably achievable and not more difficult to achieve in relation to the Company’s budget for that Performance Year than the Minimum Performance Condition and the Performance Goal for any earlier Performance Year was in relation to the budget
for that earlier Performance Year. 
 2. CONSIDERATION 
 As consideration for grant of 2013 Performance Share Units, you shall remain in the continuous employ of the Company and/or its subsidiaries or affiliates for at least one year from the Performance Cycle
Start Date or such lesser period as the Committee shall determine in its sole discretion, and no Performance Share Units shall be payable until after the completion of such one year or lesser period of employment by you (subject to
Section 6(c)). No 2014 Performance Share Units or 2015 Performance Share Units shall be granted hereunder unless you have met the one-year continuous employment requirement specified in this Section 2, measured from the Performance Cycle
Start Date. 
 3. MINIMUM PERFORMANCE CONDITION AND PERFORMANCE GOALS  

The Minimum Performance Condition and the Performance Goals for the 2013 Performance Share Units are specified on the cover page of this
Agreement and Exhibit A hereto, and for the 2014 Performance Share Units and 2015 Performance Share Units shall be specified in writing in such manner as the Committee may determine. 
 4. DETERMINATION OF PERFORMANCE SHARE UNITS EARNED AND VESTED; FORFEITURES; SETTLEMENT 
 By March 10 of the year following each Performance Year, the Committee shall determine and certify the extent to which Performance Share Units have been earned on the basis of the Company’s
actual performance in relation to (i) the established Minimum Performance Condition and (ii) the established Performance Goals for the Performance Share Units relating to that Performance Year, provided, however, that, in the case of
clause (ii), the Committee may exercise its discretion (reserved under Plan Sections 7(a) and 7(b)(v)) to reduce the amount of Performance Share Units deemed earned in 

  
 2 

 
its assessment of performance in relation to Performance Goals, or in light of other considerations the Committee deems relevant. The Committee shall certify these results in writing in
accordance with Plan Section 7(c), subject to any limitation under Section 7 hereof (if you are Disabled during the Performance Year in excess of 26 weeks). Any Performance Share Units that are not, based on the Committee’s
determination, earned by performance in a Performance Year (or deemed to be earned in connection with a termination of employment under Sections 6 and 8 below), including Performance Share Units that had been potentially earnable by performance
in excess of the actual performance levels achieved, shall be canceled and forfeited. 
 Performance Share Units are subject to
vesting based on your service for periods which extend past the applicable Performance Year. The stated vesting date is set forth on the cover page hereof. If, before the stated vesting date, there occurs an event immediately after which you are not
an employee of the Company, its subsidiaries or an affiliate of the Company, you will become vested in Performance Share Units only to the extent provided in Section 6 or 8, and any Performance Share Units that have not been earned and vested
at or before such event and which cannot thereafter be earned and vested under Sections 6 or 8 shall be canceled and forfeited. 
 In certain termination events as specified below and in connection with a long-term Disability (as defined in Section 7), you will be entitled to vesting of a “Pro Rata Portion” of the
Performance Share Units earned or deemed earned hereunder. For purposes of this Agreement, in the case of a termination of employment, the Pro Rata Portion is calculated as the proportionate number of the total number of Performance Share Units
relating to a given Performance Year; provided, however, that the number of days you were employed shall be reduced by the number of days during such Performance Year in which you were Disabled in excess of 26 weeks since the commencement of the
Disability. For purposes of this Agreement, in the case of a Disability extending longer than 26 weeks, the Pro Rata Portion is calculated as the proportionate number of the total number of Performance Share Units relating to a given Performance
Year minus the number of days you were Disabled in excess of 26 weeks since the commencement of the Disability. 
 The number of
Performance Share Units earned or vested shall be rounded to the nearest whole Performance Share Unit, unless otherwise determined by the Company officers responsible for day-to-day administration of the Plan. 

Performance Share Units that become vested while you remain employed by the Company or a subsidiary or affiliate shall be settled
promptly upon vesting, but in any event within 60 days of the vesting date, by delivery of one Share for each Performance Share Unit being settled, unless validly deferred in accordance with deferral terms then authorized by the Committee (subject
to Plan Section 11(k)). Performance Share Units that become vested under Sections 6(a), 6(b), 6(c), 6(d) or 8 shall be settled at the times specified therein; provided, however, that settlement of Performance Share Units under
Sections 6(a), (b), (c) or (d) shall be subject to the applicable provisions of Plan Section 11(k). (Note: Plan Section 11(k) could apply if settlement is triggered by a Change in Control or a termination following a
Change in Control). Until Shares are delivered to you in settlement of Performance Share Units, you shall have none of the rights of a stockholder of the Company with respect to the Shares issuable in settlement of the Performance Share Units,
including the right to vote the shares and receive distributions other than dividends. (Your rights with respect to dividends are set forth in Section 11 below.) Shares of stock issuable in settlement of Performance Share Units shall be
delivered to you upon settlement in certificated form or in such other manner as the Company may reasonably determine. 

  
 3 

 5. NONTRANSFERABILITY OF PERFORMANCE SHARE UNITS 

During the period from the Award Date until the date all of the Performance Share Units have become vested and non-forfeitable and any
further period prior to settlement of your Performance Share Units, you may not sell, transfer, pledge or assign any of the Performance Share Units or your rights relating thereto. If you attempt to assign your rights under this Agreement in
violation of the provisions herein, the Company’s obligation to settle Performance Share Units or otherwise make payments shall terminate. 

6. RETIREMENT AND OTHER TERMINATIONS (EXCLUDING DEATH) 
 (a) Retirement. In the event of your Retirement (as defined in the Plan) prior to settlement of Performance Share Units and after you have satisfied the one-year employment requirement of
Section 2, you will be deemed vested (i) in any Performance Share Units that relate to a Performance Year completed before your Retirement and which have been determined or thereafter are determined by the Committee to have been earned
under Section 4, and (ii) with respect to Performance Share Units relating to a Performance Year in progress at the date of your Retirement, in a Pro Rata Portion of the Performance Share Units you would have actually earned for that
Performance Year if you had continued to be employed through the date the Committee determines the earning of the Performance Share Units for that Performance Year under Section 4 (for this purpose, if the grant of Performance Share Units
relating to the Performance Year in progress at the date of your Retirement has not yet become effective, such grant shall be deemed to be effective immediately before the Retirement and shall have the same terms as applicable to participating
employees who remain employed). If you are employed in the United States (including in Puerto Rico), and you are not eligible for Retirement pursuant to Plan Sections 2(x)(i) and 2(x)(ii), you shall be entitled to the pro rata vesting
described in the preceding sentence only if you execute and do not revoke a release in favor of the Company and its predecessors, successors, affiliates, subsidiaries, directors and employees in a form satisfactory to the Company and, where deemed
applicable by the Company, a non-compete and/or a non-solicitation agreement; if you fail to execute or revoke the release or fail to execute the non-compete or non-solicitation agreement, you shall forfeit any Performance Share Units that are
unearned and unvested as of the date your employment terminates. Any Performance Share Units earned and vested under this Section 6(a) shall be settled at the earlier of (i) the date such Performance Share Units would have settled if you
had continued to be employed by the Company or a subsidiary or affiliate, (ii) in the event of a Change in Control, as to previously earned Performance Share Units, promptly upon the Change in Control and, in the case of any unearned
Performance Share Units (subject to Section 1), promptly following the date at which the Committee determines the extent to which such Performance Share Units have been earned (in each case subject to Section 6(e) below and Plan
Section 11(k)), or (iii) in the event of your death, in the year following the Performance Year in which your Retirement occurred (following the Committee’s determination of the extent to which any remaining unearned Performance Share
Units have been earned) or, if your death occurred after that year, as promptly as practicable following your death. Following your Retirement, any Performance Share Units that have not been earned and vested and which thereafter will not be deemed
earned and vested under this Section 6(a) will be canceled and forfeited. 
 (b) Termination by the Company Not For
Cause. In the event of your Termination Not for Cause (as defined in Section 6(f)) by the Company and not during the Protected Period (as defined in the Plan), prior to settlement of Performance Share Units and after you have satisfied the
one-year employment requirement of Section 2, you will be deemed vested (i) in any Performance Share Units that relate to a Performance Year completed before such termination and which have been determined or thereafter are determined by
the Committee to have been earned under Section 4, and (ii) with respect to Performance Share Units relating to a Performance Year in progress at the date of such termination, in a Pro Rata Portion of the Performance Share Units you would
have actually earned for that Performance Year if you had continued to be employed through the date the Committee determines the earning of the Performance 

  
 4 

 
Share Units for that Performance Year under Section 4 (for this purpose, if the grant of Performance Share Units relating to the Performance Year in progress at the date of your Termination
Not for Cause has not yet become effective, such grant shall be deemed to be effective immediately before your termination and shall have the same terms as applicable to participating employees who remain employed). If you are employed in the United
States (including in Puerto Rico), and you are not eligible for Retirement pursuant to Plan Sections 2(x)(i) and 2(x)(ii), you shall be entitled to the pro rata vesting described in the preceding sentence only if you execute and do not
revoke a release in favor of the Company and its predecessors, successors, affiliates, subsidiaries, directors and employees in a form satisfactory to the Company and, where deemed applicable by the Company, a non-compete and/or a non-solicitation
agreement; if you fail to execute or revoke the release or fail to execute the non-compete or non-solicitation agreement, you shall forfeit any Performance Share Units that are unearned and unvested as of the date your employment terminates. Any
Performance Share Units earned and vested under this Section 6(b) shall be settled at the earlier of (i) the date such Performance Share Units would have settled if you had continued to be employed by the Company or a subsidiary or
affiliate, (ii) in the event of a Change in Control meeting the conditions of Section 6(e)(ii), as to previously earned Performance Share Units, promptly upon such Change in Control and, in the case of any unearned Performance Share Units
(subject to Section 1), promptly following the date at which the Committee determines the extent to which such Performance Share Units have been earned (in each case subject to Section 6(e) below and Plan Section 11(k)), or
(iii) in the event of your death, in the year following the Performance Year in which your Termination Not for Cause occurred (following the Committee’s determination of the extent to which any remaining unearned Performance Share Units
have been earned) or, if your death occurred after that year, as promptly as practicable following your death. Following such Termination Not for Cause, any Performance Share Units that have not been earned and vested and which thereafter will not
be deemed earned and vested under this Section 6(b) will be canceled and forfeited. 
 (c) Qualifying Termination
Following a Change in Control. In the event that you have a Qualifying Termination as defined in Plan Section 9(c) during the Protected Period (as defined in the Plan) following a Change in Control (as defined in the Plan), you will be
deemed vested (i) in any Performance Share Units that relate to a Performance Year completed before such termination and which have been determined or thereafter are determined by the Committee to have been earned under Section 4, and
(ii) with respect to Performance Share Units relating to a Performance Year in progress at the date of your Qualifying Termination (subject to Section 1, but including Performance Share Units otherwise not meeting the one-year requirement
of Section 2), in a Pro Rata Portion of the target number of Performance Share Units that could have been earned in the Performance Year. All of your earned and vested Performance Share Units shall be settled promptly (subject to
Section 6(e) below and Plan Section 11(k)); provided, however, any additional forfeiture conditions in the nature of a “clawback” or recoupment contained in Section 10 of this Agreement shall continue to apply to any
payment. Upon your Qualifying Termination, any Performance Share Units that have not been deemed earned and vested under this Section 6(c) will be canceled and forfeited. 
 (d) Other Terminations. If you cease to be an employee of the Company and its subsidiaries and affiliates for any reason other than Retirement, Termination Not for Cause, a Qualifying Termination
within the Protected Period following a Change in Control, or death, Performance Share Units granted herein that have not become both earned and vested shall be canceled and forfeited and you shall have no right to settlement of any portion of the
Performance Share Units; provided however, in the event of your voluntary termination after January 1, 2016, you will continue to vest (subject to the following sentence) in any Performance Share Units that relate to a Performance Year
completed before such termination and which have been determined or thereafter are determined by the Committee to have been earned under Section 4, and any Performance Share Units earned and vested under this proviso shall be settled at the
earlier of (i) the date such Performance Share Units would have settled if you had continued to be employed by the Company or a subsidiary or affiliate, (ii) in the event of a Change in Control meeting the conditions of
Section 6(e)(ii), as to previously earned Performance Share Units, promptly upon such 

  
 5 

 
Change in Control and, in the case of any unearned Performance Share Units (subject to Section 1), promptly following the date at which the Committee determines the extent to which such
Performance Share Units have been earned (in each case subject to Section 6(e) below and Plan Section 11(k)), or (iii) in the event of your death, as promptly as practicable following the date at which the Committee determines the
extent to which any remaining unearned Performance Share Units have been earned. 
 (e) Special Distribution Rules to Comply
with Code Section 409A. The Performance Share Units constitute a “deferral of compensation” under Section 409A of the Internal Revenue Code (the “Code”), based on Internal Revenue Service regulations and guidance in
effect on the Award Date. As a result, the timing of settlement of your Performance Share Units will be subject to applicable limitations under Code Section 409A. Specifically, each tranche of Performance Share Units will be subject to Plan
Section 11(k), including the following restrictions on settlement: 
 (i) Settlement of the Performance Share Units under
Section 6(c) upon a Qualifying Termination will be subject to the requirement that the termination constitute a “separation from service” under Treas. Reg. § 1.409A-1(h), and subject to the six-month delay rule under Plan
Section 11(k)(i)(C)(2) if at the time of separation from service you are a “Specified Employee.” 
 (ii)
Settlement of the Performance Share Units under Sections 6(a), 6(b) or 6(d) in the event of a Change in Control will occur only if an event relating to the Change in Control constitutes a change in ownership or effective control of the Company
or a change in the ownership of a substantial portion of the assets of the Company within the meaning of Treas. Reg. § 1.409A-3(i)(5). 
 (f) Definition of “Termination Not for Cause.” For purposes of this Section 6, a “Termination Not for Cause” means a Company-initiated termination for reason other than
willful misconduct, activity deemed detrimental to the interests of the Company, or disability, provided that you execute a general release and, where required by the Company, a non-solicitation and/or non-compete agreement with the Company.

 (g) Determination of Termination Date. For purposes of the Performance Share Units, your employment will be considered
terminated as of the date you are no longer actively providing services to the Company or one of its subsidiaries or affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment
laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, your right to vest in the Performance Share Units under the
Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., your period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under
employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any); the Company shall have the exclusive discretion to determine when you are no longer actively providing services for purposes of your
Performance Share Units (including whether you may still be considered to be providing services while on a leave of absence). 
 7.
DISABILITY OF PARTICIPANT 
 For purposes of this Agreement, “Disability” or “Disabled” shall mean
qualifying for and receiving payments under a disability plan of the Company or any subsidiary or affiliate either in the United States or in a jurisdiction outside of the United States, and in jurisdictions outside of the United States shall also
include qualifying for and receiving payments under a mandatory or universal disability plan or program managed or maintained by the government. If you become Disabled, you will not be deemed to have terminated employment for the period during
which, under the applicable Disability pay plan of the Company or a subsidiary or affiliate, you are deemed to be employed and continue to receive 

  
 6 

 
Disability payments. Upon the cessation of payments under such Disability pay plan, (i) if you return to employment status with the Company or a subsidiary or affiliate, you will not be
deemed to have terminated employment, and (ii) if you do not return to such employment status, you will be deemed to have terminated employment at the date of cessation of such Disability payments, with such termination treated for purposes of
the Performance Share Units as a Retirement, death, or voluntary termination based on your circumstances at the time of such termination. If you have been Disabled for a period in excess of 26 weeks in the aggregate during one or more
Performance Years, for each affected Performance Year you will earn only a Pro Rata Portion of the Performance Share Units you otherwise would have earned in respect of such a Performance Year. 

8. DEATH OF PARTICIPANT 

In the event of your death while employed by the Company or a subsidiary and prior to settlement of Performance Share Units but after you
have satisfied the one-year employment requirement of Section 2, you will be deemed vested (i) in any Performance Share Units that relate to a Performance Year completed before your death and which have been determined or thereafter are
determined by the Committee to have been earned under Section 4, and (ii) with respect to Performance Share Units relating to a Performance Year in progress at the date of your death, in a Pro Rata Portion of the Performance Share Units
you would have actually earned for that Performance Year if you had continued to be employed through the date the Committee determines the earning of the Performance Share Units for that Performance Year under Section 4. In this case, your
beneficiary shall be entitled to settlement of any of your earned and vested Performance Share Units referred to in clause (i) by the later of the end of the calendar year in which your death occurred or 60 days after your death, and to your
earned and vested Performance Share Units referred to in clause (ii) in the year following your year of death as promptly as practicable following the determination of the number of Performance Share Units earned under clause (ii) above.
In the case of your death, any Performance Share Units that have not been earned and vested and thereafter will not be deemed earned and vested under this Section 8 will be canceled and forfeited. 

9. RESPONSIBILITY FOR TAXES 
 You acknowledge that, regardless of any action taken by the Company, any subsidiary or affiliate or your employer (“Employer”), the ultimate liability for all income tax (including federal,
state, local and non-U.S. taxes), social security, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you or deemed by the Company or the Employer to be
an appropriate charge to you even if legally applicable to the Company or the Employer (“Tax-Related Items”), is and remains your responsibility and may exceed the amount actually withheld by the Company or the Employer. You further
acknowledge that the Company, any subsidiary or affiliate and/or the Employer: (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Performance Share Units, including
the grant of the Performance Share Units, the vesting of Performance Share Units, the conversion of the Performance Share Units into Shares or the receipt of an equivalent cash payment, the subsequent sale of any Shares acquired at settlement and
the receipt of any dividends and/or dividend equivalents; and, (b) do not commit to structure the terms of the grant or any aspect of the Performance Share Units to reduce or eliminate your liability for Tax-Related Items or achieve any
particular tax result. Further, if you are subject to Tax-Related Items in more than one jurisdiction between the Award Date and the date of any relevant taxable event, you acknowledge that the Company and/or the Employer (or former employer, as
applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction. 
 Prior to the relevant
taxable event, you agree to make adequate arrangements satisfactory to the Company or the Employer to satisfy all Tax-Related Items. In this regard, by your acceptance of the Performance Share Units, you authorize the Company and/or the Employer, or
their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following: 
  

	 	(a)	withholding from your wages or other cash compensation paid to you by the Company and/or the Employer; or 

  
 7 

	 	(b)	withholding from proceeds of the sale of Shares acquired upon settlement of the Performance Share Units either through a voluntary sale or through a mandatory sale
arranged by the Company (on your behalf pursuant to this authorization without further consent); or 

  

	 	(c)	withholding in Shares to be issued upon settlement of the Performance Share Units; provided, however, if you are a Section 16 officer of the Company under the
Securities Exchange Act of 1934, as amended, then the Company will withhold Shares upon the relevant taxable or tax withholding event, as applicable, unless the use of such withholding method is problematic under applicable tax or securities law or
has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by one or a combination of methods (a) and (b) above. 

Depending on the withholding method, the Company may withhold or account for Tax-Related Items by considering applicable minimum
statutory withholding rates or other applicable withholding rates, including maximum applicable rates, in which case you will receive a refund of any over-withheld amount in cash and will have no entitlement to the Share equivalent. If the
obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, you are deemed to have been issued the full number of Shares subject to the vested Performance Share Units, notwithstanding that a number of the Shares are
held back solely for the purpose of paying the Tax-Related Items. 
 Finally, you agree to pay to the Company or the Employer,
including through withholding from your wages or other cash compensation paid to you by the Company and/or the Employer, any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your
participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares, if you fail to comply with your obligations in connection with the
Tax-Related Items. 
 Notwithstanding anything in this Section 9 to the contrary, to avoid a prohibited acceleration under
Code Section 409A, if Shares subject to the Performance Share Units will be sold on your behalf (or withheld) to satisfy any Tax-Related Items arising prior to the date of settlement of the Performance Share Units for any portion of the
Performance Share Units that is considered nonqualified deferred compensation subject to Code Section 409A, then the number of shares sold on your behalf (or withheld) shall not exceed the number of shares that equals the liability for
Tax-Related Items. 
 10. FORFEITURE IN THE EVENT OF COMPETITION AND/OR SOLICITATION OR OTHER ACTS 

You acknowledge that your continued employment with the Company and its subsidiaries and affiliates and this grant of Performance Share
Units are sufficient consideration for this Agreement, including, without limitation, the restrictions imposed upon you by this Section 10. 
  

	 	(a)	By accepting the Performance Share Units granted hereby, you expressly agree and covenant that during the Restricted Period (as defined below), you shall not, without
the prior consent of the Company, directly or indirectly: 

  

	 	(i)	own or have any financial interest in a Competitive Business (as defined below), except that nothing in this clause shall prevent you from owning one percent or less of
the outstanding securities of any entity whose securities are traded on a U.S. national securities exchange (including NASDAQ) or an equivalent foreign exchange; 

  
 8 

	 	(ii)	be actively connected with a Competitive Business by managing, operating, controlling, being an employee or consultant (or accepting an offer to be an employee or
consultant) or otherwise advising or assisting a Competitive Business in such a way that such connection might result in an increase in value or worth of any product, technology or service, that competes with any product, technology or service upon
which you worked or about which you became familiar as a result of your employment with the Company or a subsidiary or affiliate. You may, however, be actively connected with a Competitive Business after your employment with the Company or a
subsidiary terminates for any reason, so long as your connection to the business does not involve any product, technology or service, that competes with any product, technology or service upon which you worked or about which you became familiar as a
result of your employment with the Company or a subsidiary and the Company is provided written assurances of this fact from the Competing Company prior to your beginning such connection; 

 

	 	(iii)	take any action that might divert any opportunity from the Company or any of its affiliates, successors or assigns (the “Related Parties”) that is within the
scope of the present or future operations or business of any Related Parties; 

  

	 	(iv)	employ, solicit for employment, advise or recommend to any other person that they employ or solicit for employment or form an association with any person who is
employed by the Company or its Related Parties or who has been employed by the Company or its Related Parties within one year of the date your employment with the Company or a subsidiary ceased for any reason whatsoever; 

 

	 	(v)	contact, call upon or solicit any customer of the Company, or attempt to divert or take away from the Company the business of any of its customers;

  

	 	(vi)	contact, call upon or solicit any prospective customer of the Company that you became aware of or were introduced to in the course of your duties for the Company or its
Related Parties, or otherwise divert or take away from the Company the business of any prospective customer of the Company; or 

  

	 	(vii)	engage in any activity that is harmful to the interests of the Company, including, without limitation, any conduct during the term of your employment that violates the
Company’s Standards of Business Conduct and Ethics, securities trading policy and other policies. 

  

	 	(b)	Forfeiture. You agree and covenant that, if the Company determines that you have violated any provisions of Section 10(a) above during the Restricted
Period, then: 

  

	 	(i)	any portion of the Performance Share Units that have not been settled or paid to you as of the date of such determination shall be immediately canceled and forfeited;

  

	 	(ii)	you shall automatically forfeit any rights you may have with respect to the Performance Share Units as of the date of such determination; 

 

	 	(iii)	if any Performance Share Units have become vested within the twelve-month period immediately preceding a violation of Section 10(a) above (or following the date of
any such violation), upon the Company’s demand, you shall immediately deliver to it a certificate or certificates for Shares equal to the number of Shares delivered to you in settlement of such vested Performance Share Units if such delivery
was made in Shares or you shall pay cash equal to the value of cash paid to you in settlement of such vested Performance Share Units if such payment was made in cash; and 

  
 9 

	 	(iv)	the foregoing remedies set forth in this Section 10(b) shall not be the Company’s exclusive remedies. The Company reserves all other rights and remedies
available to it at law or in equity. 

  

	 	(c)	Company Policy. You agree that the Company may recover any incentive-based compensation received by you under this Agreement if such recovery is pursuant to a
clawback or recoupment policy approved by the Committee. 

  

	 	(d)	Definitions. For purposes of this Section 10, the following definitions shall apply: 

 

	 	(i)	The Company directly advertises and solicits business from customers wherever they may be found and its business is thus worldwide in scope. Therefore,
“Competitive Business” means any person or entity that engages in any business activity that competes with the Company’s business in any way, in any geographic area in which the Company engages in business, including, without
limitation, any state in the United States in which the Company sells or offers to sell its products from time to time. 

  

	 	(ii)	“Restricted Period” means the period during which you are employed by the Company or its subsidiaries and affiliates and twelve months following the date that
you no longer are employed by the Company or any of its subsidiaries or affiliates for any reason whatsoever. 

  

	 	(e)	Severability. You acknowledge and agree that the period, scope and geographic areas of restriction imposed upon you by the provisions of Section 10 are fair
and reasonable and are reasonably required for the protection of the Company. In the event that any part of this Agreement, including, without limitation, Section 10, is held to be unenforceable or invalid, the remaining parts of this Agreement
and Section 10 shall nevertheless continue to be valid and enforceable as though the invalid portions were not a part of this Agreement. If any one of the provisions in Section 10 is held to be excessively broad as to period, scope and
geographic areas, any such provision shall be construed by limiting it to the extent necessary to be enforceable under applicable law. 

  

	 	(f)	Additional Remedies. You acknowledge that breach by you of this Agreement would cause irreparable harm to the Company and that in the event of such breach, the
Company shall have, in addition to monetary damages and other remedies at law, the right to an injunction, specific performance and other equitable relief to prevent violations of your obligations hereunder. 

11. DIVIDEND EQUIVALENTS AND OTHER ADJUSTMENTS 
  

	 	(a)	Crediting of Dividend Equivalents. Subject to this Section 11, dividend equivalents shall be credited on your Performance Share Units (other than
Performance Share Units that, at the relevant record date, previously have been settled or forfeited) as follows, except that the Committee may specify an alternative treatment from that specified in (i), (ii), or (iii) below for any dividend
or distribution: 

  

	 	(i)	 Cash Dividends. If the Company declares and pays a dividend or distribution on Shares in the form of cash, then a number of additional
Performance Share Units shall be credited to you as of the payment date for such dividend or distribution equal to (A) the amount of such dividend on each outstanding Share, multiplied by (B) the number of Performance Share Units credited
to you as of the record date for such dividend or distribution, divided by (C) the Fair Market Value of a Share at such payment date. At the time the underlying 

  
 10 

	 	
Performance Share Units become payable, the Company has the discretion to pay any accrued dividend equivalents either in cash or in Shares. You will be eligible to receive dividend equivalents on
any Performance Share Units credited to you under this Section 11(a)(i). For purposes of determining the number of Performance Share Units “credited” to you as of the record date of a dividend or distribution in this Section 11,
a Performance Share Unit shall not be deemed “credited” until a separate Performance Goal has been set by the Committee for such Performance Share Unit. 

 

	 	(ii)	Non-Share Dividends. If the Company declares and pays a dividend or distribution on Shares in the form of property other than shares, then a number of additional
Performance Share Units shall be credited to you as of the payment date for such dividend or distribution equal to (A) the number of Performance Share Units credited to you as of the record date for such dividend or distribution, multiplied by
(B) the Fair Market Value of such property actually paid as a dividend or distribution on each outstanding Share at such payment date, divided by (C) the Fair Market Value of a share at such payment date. You will be eligible to receive
dividend equivalents on any Performance Share Units credited to you under this Section 11(a)(ii). 

  

	 	(iii)	Common Stock Dividends and Splits. If the Company declares and pays a dividend or distribution on Shares in the form of additional shares, or there occurs a
forward split of Shares, then a number of additional Performance Share Units shall be credited to you as of the payment date for such dividend or distribution or forward split equal to (A) the number of Performance Share Units credited to you
as of the record date for such dividend or distribution or split, multiplied by (B) the number of additional shares actually paid as a dividend or distribution or issued in such split in respect of each outstanding Share. You will be eligible
to receive dividend equivalents on any Performance Share Units credited to you under this Section 11(a)(iii). 

  

	 	(b)	Adjustment of Dividend Equivalents. If any Performance Share Unit is forfeited for any reason, including as a result of the failure to attain the Minimum
Performance Condition or the failure to attain the Performance Goals at least at Threshold, any dividend or distribution attributable to such Performance Share Unit, whether in the form of cash or additional Performance Share Units, shall be
forfeited on the date on which the underlying Performance Share Unit is forfeited. If any Performance Share Units are paid at greater or smaller than 100% of Target, the amount of dividend equivalents (if any) credited on such Performance Share
Units, whether in the form of cash or additional Performance Share Units, shall be increased or decreased proportionately to reflect the payout percentage on the underlying Performance Share Units. 

 

	 	(c)	Payment of Dividend Equivalents. Any cash payable under this Section 11 shall be included as part of your regular payroll payment as soon as
administratively practicable after the settlement date for the underlying Performance Share Units. Any Performance Share Units payable under this Section 11 shall be settled on the settlement date for the underlying Performance Share Unit. When
the dividend equivalents you receive under this Section 11, if any, become payable to you, they will be compensation (wages) for tax purposes and, if you are a U.S. taxpayer, will be included on your W-2 form. The Company will be required to
withhold applicable taxes on such dividend equivalents. The Company may deduct such taxes in the manner set forth in Section 9 hereof. 

  

	 	(d)	 Other Adjustments. The target number of Performance Share Units, the kind of securities deliverable in settlement of Performance Share
Units, and any performance measure based on per share results shall be appropriately adjusted in order to prevent dilution or enlargement of your rights with respect to the Performance Share Units upon the occurrence of an event referred to in

  
 11 

	 	
Plan Section 11(c). In furtherance of the foregoing, in the event of an equity restructuring, as defined in FASB ASC Topic 718, which affects the Shares, you shall have a legal right to an
adjustment to your Performance Share Units which shall preserve without enlarging the value of the Performance Share Units, with the manner of such adjustment to be determined by the Committee in its discretion. Any Performance Share Units or
related rights which directly or indirectly result from an adjustment to a Performance Share Unit hereunder shall be subject to the same risk of forfeiture and other conditions as apply to the granted Performance Share Unit and will be settled at
the same time as the granted Performance Share Unit. 

 12. EFFECT ON OTHER BENEFITS 

In no event shall the value, at any time, of the Performance Share Units or any other payment or right to payment under this Agreement be
included as compensation or earnings for purposes of any other compensation, retirement, or benefit plan offered to employees of the Company or its subsidiaries or affiliates unless otherwise specifically provided for in such plan. Performance Share
Units and the income and value of the same are not part of normal or expected compensation or salary for any purposes including, but not limited to, calculation of any severance, resignation, termination, redundancy or end-of-service payments,
bonuses, long-service awards, pension or retirement benefits, or similar payments. 
 13. ACKNOWLEDGMENT OF NATURE OF PLAN AND PERFORMANCE
SHARE UNITS 
 In accepting the Performance Share Units, you acknowledge, understand and agree that: 

(a) The Plan is established voluntarily by the Company, it is discretionary in nature and may be modified, amended, suspended or
terminated by the Company at any time, to the extent permitted by the Plan; 
 (b) The award of Performance Share Units is
voluntary and occasional and does not create any contractual or other right to receive future awards of Performance Share Units, or benefits in lieu of Performance Share Units even if Performance Share Units have been awarded in the past;

 (c) All decisions with respect to future awards of Performance Share Units or other awards, if any, will be at the sole
discretion of the Company; 
 (d) Your participation in the Plan is voluntary; 

(e) The Performance Share Units and the Shares subject to the Performance Share Units are not intended to replace any pension rights or
compensation; 
 (f) The future value of the underlying Shares is unknown, indeterminable and cannot be predicted with
certainty; 
 (g) No claim or entitlement to compensation or damages arises from the forfeiture of Performance Share Units,
resulting from termination of your employment or other service relationship with the Company, or any of its subsidiaries or affiliates or the Employer (for any reason whatsoever and whether or not later found to be invalid or in breach of employment
laws in the jurisdiction where you are employed or the terms of your employment agreement, if any) and in consideration of the grant of the Performance Share Units to which you are otherwise not entitled, you irrevocably agree never to institute any
claim against the Company, any of its subsidiaries or affiliates or the Employer, waive your ability, if any, to bring such claim, and release the Company, any subsidiary or affiliate and/or the Employer from any such claim; if, notwithstanding the
foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, you shall be deemed irrevocably to have agreed not to pursue such claim and agree to execute any and all documents necessary to request
dismissal or withdrawal of such claim; 

  
 12 

 (h) Unless otherwise provided in the Plan or by the Company in its discretion, the
Performance Share Units and the benefits evidenced by this Agreement do not create any entitlement to have the Performance Share Units or any such benefits transferred to, or assumed by, another company nor to be exchanged, cashed out or substituted
for, in connection with any corporate transaction affecting the shares of the Company; and 
 (i) The following provisions apply
only if you are providing services outside the United States: (i) the award and the Shares subject to the Performance Share Units are not part of normal or expected compensation or salary for any purpose; and (ii) you acknowledge and agree
that neither the Company, the Employer nor any subsidiary or affiliate of the Company shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the Performance
Share Units or of any amounts due to you pursuant to the settlement of the Performance Share Units or the subsequent sale of any Shares acquired upon settlement. 
 14. NO ADVICE REGARDING GRANT 
 The Company is not providing any tax, legal
or financial advice, nor is the Company making any recommendations regarding your participation in the Plan or your acquisition or sale of the underlying Shares. You are hereby advised to consult with your own personal tax, legal and financial
advisors regarding your participation in the Plan before taking any action related to the Plan. 
 15. RIGHT TO CONTINUED EMPLOYMENT

 Nothing in the Plan or this Agreement shall confer on you any right to continue in the employ of the Company or any
subsidiary or affiliate or any specific position or level of employment with the Company or any subsidiary or affiliate or affect in any way the right of the Company or any subsidiary or affiliate to terminate your employment without prior notice at
any time for any reason or no reason. 
 16. ADMINISTRATION 
 The Committee shall have full authority and discretion, subject only to the express terms of the Plan, to decide all matters relating to the administration and interpretation of the Plan and this
Agreement, and all such Committee determinations shall be final, conclusive, and binding upon the Company, any subsidiary or affiliate, you, and all interested parties. Any provision for distribution in settlement of your Performance Share Units and
other obligations hereunder shall be by means of bookkeeping entries on the books of the Company and shall not create in you or any beneficiary any right to, or claim against any, specific assets of the Company, nor result in the creation of any
trust or escrow account for you or any beneficiary. You and any of your beneficiaries entitled to any settlement or other payment hereunder shall be a general creditor of the Company. 
 17. DEEMED ACCEPTANCE 
 You are required to accept the terms and conditions
set forth in this Agreement prior to the end of the first Performance Year in order for you to receive the Award granted to you hereunder. If you wish to decline this Award, you must reject this Agreement prior to the end of the first Performance
Year. For your benefit, if you have not rejected the Agreement prior to the end of the first Performance Year, you will be deemed to have automatically accepted this Award and all the terms and conditions set forth in this Agreement. Deemed
acceptance will allow the shares to be released to you in a timely manner. 

  
 13 

 18. AMENDMENT TO PLAN 
 This Agreement shall be subject to the terms of the Plan, as amended from time to time, except that, subject to Sections 25 and 28 below, Performance Share Units which are the subject of this
Agreement may not be materially adversely affected by any amendment or termination of the Plan approved after the Award Date without your written consent. 
 19. SEVERABILITY AND VALIDITY 
 The various provisions of this Agreement
are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable. 

20. GOVERNING LAW, JURISDICTION AND VENUE 
 This Agreement and Award grant shall be governed by the substantive laws (but not the choice of law rules) of the State of New York. For purposes of litigating any dispute that arises under this
Performance Share Unit grant or Agreement, the parties hereby submit to and consent to the jurisdiction of the State of New York, agree that such litigation shall be conducted in the courts of New York, New York, or the federal courts for the United
States for the Southern District of New York, and no other courts where this Performance Share Unit grant is made and/or performed. 
 21.
SUCCESSORS 
 This Agreement shall be binding upon and inure to the benefit of the successors, assigns, and heirs of the
respective parties. 
 22. DATA PRIVACY 
 You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement by and among, as applicable, your
Employer, the Company and its subsidiaries for the exclusive purpose of implementing, administering and managing your participation in the Plan. 
 You understand that the Company, any subsidiary and/or your Employer may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of
birth, social security number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company, details of all Performance Share Units or any other entitlement to shares awarded, canceled,
vested, unvested or outstanding in your favor, for the purpose of implementing, administering and managing the Plan (“Data”). 
 You understand that Data may be transferred to Morgan Stanley Smith Barney, or such other stock plan service provider as may be selected by the Company in the future, which assists in the implementation,
administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipient’s country (e.g. the United States) may have different data privacy laws and
protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You
authorize the Company, Morgan Stanley Smith Barney and other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data,
in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan, including any requisite transfer of such Data as may be required to a broker, escrow agent or other third party with whom
the Shares received upon 

  
 14 

 
vesting of the Performance Share Units may be deposited. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You
understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in
any case without cost, by contacting your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your
employment status or service and career with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company would not be able to grant you Performance Share Units or other equity
awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal
of consent, you understand that you may contact your local human resources representative. 
 23. ELECTRONIC DELIVERY AND ACCEPTANCE

 The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the
Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic systems established and maintained by the Company or a third-party designated by the
Company. 
 24. LANGUAGE 
 If you have received this Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English
version, the English version will control. 
 25. COMPLIANCE WITH LAWS AND REGULATIONS 

Notwithstanding any other provisions of the Plan or this Agreement, unless there is an available exemption from any registration,
qualification or other legal requirement applicable to the Shares, you understand that the Company will not be obligated to issue any Shares pursuant to the vesting and settlement of the Performance Share Units, if the issuance of such Shares shall
constitute a violation by you or the Company of any provision of law or regulation of any governmental authority. Further, you agree that the Company shall have unilateral authority to amend the Plan and the Agreement without your consent to the
extent necessary to comply with securities or other laws applicable to issuance of shares. Any determination by the Company in this regard shall be final, binding and conclusive. 
 26. ENTIRE AGREEMENT AND NO ORAL MODIFICATION OR WAIVER 
 This Agreement
contains the entire understanding of the parties. This Agreement shall not be modified or amended except in writing duly signed by the parties except that the Company may adopt a modification or amendment to the Agreement that is not materially
adverse to you in writing signed only by the Company. Any waiver of any right or failure to perform under this Agreement shall be in writing signed by the party granting the waiver and shall not be deemed a waiver of any subsequent failure to
perform. 
 27. ADDENDUM 
 Your Performance Share Units shall be subject to any special provisions set forth in the Addendum to this Agreement for your country, if any. If you relocate to one of the countries included in the
Addendum during any Performance Year, the special provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable for legal or administrative reasons. The
Addendum, if any, constitutes part of this Agreement. 

  
 15 

 28. IMPOSITION OF OTHER REQUIREMENTS 

The Company reserves the right to impose other requirements on your participation in the Plan, on the Performance Share Units and on any
Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the
foregoing. 
  

			
	For the Company
	
	Bristol-Myers Squibb Company
		
	By:  	 	 

 I have read this Agreement in its entirety. I understand that this Award has been granted to provide a means for me
to acquire and/or expand an ownership position in Bristol-Myers Squibb Company. I acknowledge and agree that sales of shares will be subject to the Company’s policies regulating trading by employees. In accepting this Award, I hereby agree that
Morgan Stanley Smith Barney, or such other vendor as the Company may choose to administer the Plan, may provide the Company with any and all account information for the administration of this Award. 

I hereby agree to all the terms, restrictions and conditions set forth in the Agreement. 

  
 16 

 Exhibit A 
 PERFORMANCE SHARE UNITS AGREEMENT 
 Under the Bristol-Myers Squibb Company

 2012 Stock Award and Incentive Plan 
 2013-2015 Performance Share Units Award 
 2013 Minimum Performance
Condition and Performance Goals 
 If Participant has been designated a Covered Employee (as defined in the Plan) for the 2013 Performance
Year, then a required condition in order for Participant to earn 2013 Performance Share Units in the manner set forth below will be that the Company’s Non-GAAP Pretax Earnings for the 2013 fiscal year shall equal or exceed
$[            ] (the “Minimum Performance Condition”). If Participant has not been designated a Covered Employee for the 2013 Performance Year, then Participant shall earn
2013 Performance Share Units in the manner set forth below. 
 The number of 2013 Performance Share Units earned by Participant shall be
determined as of December 31, 2013 (the “Earning Date”), based on the Company’s 2013 Net Sales Performance (net of foreign exchange), 2013 Non-GAAP Diluted EPS Performance, and 2013 Adjusted Net Cash Flow from Operating
Activities Performance, each as defined below, determined based on the following grid: 
  

							
	 Performance Measure
	  	Threshold	  	Target	  	Maximum
	 2013 Net Sales, net of fx ($=MM)
	  		  		  	
	 2013 Non-GAAP Diluted EPS
	  		  		  	
	 2013 Adjusted Net Cash Flow from Operating Activities ($=MM)
	  		  		  	

 Participant shall earn 32.50% of the target number of 2013 Performance Share Units for “Threshold Performance,”
100% of the target number of 2013 Performance Share Units for “Target Performance,” and 167.50% of the target number of 2013 Performance Share Units for “Maximum Performance.” For this purpose, 2013 Net Sales Performance and 2013
Adjusted Net Cash Flow from Operating Activities Performance are weighted 25% each, and 2013 Non-GAAP Diluted EPS Performance is weighted 50%, so the level of earning of 2013 Performance Share Units shall be determined on a weighted-average basis.

 Determinations of the Committee regarding 2013 Non-GAAP Pretax Earnings, 2013 Net Sales Performance, 2013 Non-GAAP Diluted EPS Performance,
and 2013 Adjusted Net Cash Flow from Operating Activities Performance, and the resulting 2013 Performance Share Units earned, and related matters, will be final and binding on Participant. In making its determinations with respect to 2013 Net Sales
Performance, 2013 Non-GAAP Diluted EPS Performance, and 2013 Adjusted Net Cash Flow from Operating Activities Performance, the Committee may exercise its discretion (reserved under Plan Sections 7(a) and 7(b)(v)) to reduce the amount of
Performance Share Units deemed earned, in its sole discretion. 

  
 A-1

 Addendum 
 BRISTOL-MYERS SQUIBB COMPANY 
 SPECIAL PROVISIONS FOR PERFORMANCE SHARE
UNITS IN CERTAIN COUNTRIES 
 This Addendum includes special country-specific terms that apply to residents in the countries listed below.
This Addendum is part of the Agreement. Unless otherwise provided below, capitalized terms used but not defined herein shall have the same meanings assigned to them in the Plan and the Agreement. 

This Addendum also includes information of which you should be aware with respect to your participation in the Plan. For example, certain individual
exchange control reporting requirements may apply upon vesting of the Performance Share Units and/or sale of Shares. The information is based on the securities, exchange control and other laws in effect in the respective countries as of
January 2013 and is provided for informational purposes. Such laws are often complex and change frequently, and results may be different based on the particular facts and circumstances. As a result, the Company strongly recommends that you do
not rely on the information noted herein as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time your Performance Share Units vest or are settled, or you
sell Shares acquired under the Plan. 
 In addition, the information is general in nature and may not apply to your particular situation, and
the Company is not in a position to assure you of any particular result. Accordingly, you are advised to seek appropriate professional advice as to how the relevant laws in your country may apply to your situation. 

Finally, if you are a citizen or resident of a country other than the one in which you currently are working, transfer employment after the Performance
Share Units are granted to you, or are considered a resident of another country for local law purposes, the information contained herein for the country you are working in at the time of grant may not be applicable to you, and the Company shall, in
its discretion, determine to what extent the terms and conditions contained herein shall be applicable to you. If you transfer residency and/or employment to another country or are considered a resident of another country listed in the Addendum
after the Performance Share Units are granted to you, the terms and/or information contained for that new country (rather than the original grant country) may be applicable to you. 

Algeria 
 Exchange
Control Information. Proceeds from the sale of Shares and the receipt of any dividends must be repatriated to Algeria. 

Argentina 
 Securities
Law Information. Neither the Performance Share Units nor the underlying Shares are publicly offered or listed on any stock exchange in Argentina. The offer is private and not subject to the supervision of any Argentine governmental authority.

 Exchange Control Information. In the event that you transfer proceeds from the sale of Shares or any cash dividends paid on such
shares into Argentina within 10 days of receipt (i.e., if the proceeds have not been held in the offshore bank or brokerage account for at least 10 days prior to transfer), you will be required to deposit 30% of any proceeds in a
non-interest bearing deposit account for a 365 day holding period. In any event, the Argentine bank handling the transaction may request certain documentation in connection with your request to transfer proceeds into Argentina, including evidence of
the sale and proof that no funds were remitted out of Argentina to acquire the Shares. If the bank determines that the 10-day rule or any other rule or regulation promulgated by the Argentine Central Bank has not been satisfied, it may require that
30% of the proceeds be placed in a non-interest bearing dollar denominated mandatory 

  
 Addendum-1

 
deposit account for a holding period of 365 days. Please note that exchange control regulations in Argentina are subject to frequent change. You are solely responsible for complying with any
exchange control laws that may apply to you as a result of participating in the Plan and/or the transfer of funds in connection with the award. You should consult with your personal legal advisor regarding any exchange control obligations that you
may have. 
 Australia 
 Securities Law Information. If you acquire Shares pursuant to your Performance Share Units and you offer your Shares for sale to a person or entity resident in Australia, your offer may be subject
to disclosure requirements under Australian law. You should obtain legal advice on your disclosure obligations prior to making any such offer. 

Exchange Control Information. Exchange control reporting is required for cash transactions exceeding AUD10,000 and for international fund
transfers. The Australian bank assisting with the transaction will file the report for you. If there is no Australian bank involved in the transfer, you will have to file the report. 

Austria 
 Exchange
Control Information. If you hold Shares purchased under the Plan outside of Austria (even if you hold them outside of Austria at a branch of an Austrian bank), you will be required to submit a report to the Austrian National Bank as follows:
(i) on a quarterly basis if the value of the Shares as of any given quarter exceeds €30,000,000; and (ii) on an annual basis if the value of the Shares as of December 31 exceeds €5,000,000. 

When Shares are sold, there may be exchange control obligations if the cash proceeds from the sale are held outside Austria. If the transaction volume of
all your cash accounts abroad exceeds €3,000,000, the movements and the balance of all accounts must be reported monthly, as of the last day of the month, on or before the fifteenth day of the following month. If the transaction value of all
cash accounts abroad is less than €3,000,000, no ongoing reporting requirements apply. 
 Belgium 

Tax Reporting Information. If you are a Belgian resident, you are required to report any security or bank account (including brokerage accounts)
you maintain outside of Belgium on your annual tax return. 
 Brazil 

Compliance with Laws. By accepting the Performance Share Units, you agree that you will comply with Brazilian law when you vest in the Performance
Share Units and sell Shares. You also agree to report and pay any and all taxes associated with the vesting of the Performance Share Units, the sale of the Shares acquired pursuant to the Plan and the receipt of any dividends or Dividend
Equivalents. 
 Exchange Control Information. You must prepare and submit a declaration of assets and rights held outside of Brazil to
the Central Bank on an annual basis if you hold assets or rights valued at more than US$100,000. The assets and rights that must be reported include Shares. 
 Canada 
 Settlement of Performance Share Units. Notwithstanding any terms or
conditions of the Plan or the Agreement to the contrary, Performance Share Units will be settled in Shares only, not cash. 

  
 Addendum-2

 Securities Law Information. You acknowledge and agree that you will only sell Shares acquired through
participation in the Plan outside of Canada through the facilities of a stock exchange on which the Shares are listed. Currently, the Shares are listed on the New York Stock Exchange. 
 Termination of Employment. This provision supplements Section 6(g) of the Agreement: 

In the event of your termination of employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in
breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), your right to vest in the Performance Share Units will terminate effective as of the date that is the earlier of (1) the
date you are no longer actively providing service or, (2) the date you receive notice of termination of employment from the Employer, regardless of any notice period or period of pay in lieu of such notice required under applicable laws
(including, but not limited to statutory law, regulatory law and/or common law); the Company shall have the exclusive discretion to determine when you are no longer actively employed for purposes of the Performance Share Units. 

The following provisions apply if you are resident in Quebec: 
 Language Acknowledgment 
 The parties acknowledge that it is their express wish that this
Agreement, including this Addendum, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be provided to them in English. 

Consentement relatif à la langue utilisée. Les parties reconnaissent avoir expressément souhaité que la convention
(«Agreement») ainsi que cette Annexe, ainsi que tous les documents, avis et procédures judiciares, éxécutés, donnés ou intentés en vertu de, ou liés directement ou indirectement à
la présente convention, soient rédigés en langue anglaise. 
 Data Privacy. This provision supplements
Section 22 of the Agreement: 
 You hereby authorize the Company, the Employer and their representatives to discuss with and obtain all
relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company and its subsidiaries to disclose and discuss the Plan with their advisors. You further
authorize the Company and its subsidiaries to record such information and to keep such information in your employee file. 

Chile 
 Securities Law
Information. Neither the Company, the Performance Share Units nor the Shares you may acquire upon vesting of your Performance Share Units are registered with the Registry of Securities or under the control of the Chilean Superintendence of
Securities. 
 Exchange Control and Tax Information. You are not required to repatriate proceeds obtained from the sale of Shares or from
dividends to Chile; however, if you decide to repatriate proceeds from the sale of Shares and/or dividends and the amount of the proceeds to be repatriated exceeds US$10,000, you acknowledge that you must effect such repatriation through the Formal
Exchange Market (i.e., a commercial bank or registered foreign exchange office). 
 Further, if the value of your aggregate investments
held outside of Chile exceeds US$5,000,000 (including the value of Shares acquired under the Plan), you must report the status of such investments annually to the Central Bank using Annex 3.1 of Chapter XII of the Foreign Exchange Regulations.

  
 Addendum-3

 Finally, if you hold Shares acquired under the Plan outside of Chile, you must inform the Chilean Internal
Revenue Service (the “CIRS”) of the details of your investment in the Shares by Filing Tax Form 1851 “Annual Sworn Statement Regarding Investments Held Abroad.” Further, if you wish to receive credit against your Chilean
income taxes for any taxes paid abroad, you must report the payment of taxes abroad to the CIRS by filing Tax Form 1853 “Annual Sworn Statement Regarding Credits for Taxes Paid Abroad.” These statements must be submitted
electronically through the CIRS website before March 15 of each year. 
 China 

The following provisions apply if you are subject to the exchange control regulations in China, as determined by the Company in its sole discretion:

 Settlement of Performance Share Units and Sale of Shares. Due to local regulatory requirements, upon the vesting of the Performance
Share Units, you agree to the immediate sale of any Shares to be issued to you upon vesting and settlement of the Performance Share Units. You further agree that the Company is authorized to instruct its designated broker to assist with the
mandatory sale of such Shares (on your behalf pursuant to this authorization) and you expressly authorize the Company’s designated broker to complete the sale of such Shares. You acknowledge that the Company’s designated broker is under no
obligation to arrange for the sale of the Shares at any particular price. Upon the sale of the Shares, the Company agrees to pay you the cash proceeds from the sale of the Shares, less any brokerage fees or commissions and subject to any obligation
to satisfy Tax-Related Items. 
 Treatment of Performance Share Units Upon Termination of Employment. Notwithstanding anything in the
Agreement to the contrary, upon termination of your employment, you will forfeit any Pro Rata Portion of Performance Share Units vesting after your termination of employment. Any Performance Share Units earned but unvested as of your termination of
employment will vest immediately upon such termination date and the distributed Shares will be sold immediately upon vesting, as described above. You will not continue to vest in Performance Share Units or be entitled to any Pro Rata Portion of
Performance Share Units after your termination of employment. Any Shares distributed to you according to this paragraph will be sold immediately upon distribution, as described above. 
 Exchange Control Information. You understand and agree that, to facilitate compliance with exchange control requirements, you will be required to immediately repatriate to China the cash proceeds
from the immediate sale of the Shares issued upon the vesting of the Performance Share Units. You further understand that, under local law, such repatriation of the cash proceeds will be effectuated through a special exchange control account
established by the Company or its subsidiaries, and you hereby consent and agree that the proceeds from the sale of Shares acquired under the Plan may be transferred to such special account prior to being delivered to you. The Company may deliver
the proceeds to you in U.S. dollars or local currency at the Company’s discretion. If the proceeds are paid in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China so that the proceeds may be
deposited into this account. If the proceeds are converted to local currency, there may be delays in delivering the proceeds to you and due to fluctuations in the Shares trading price and/or the U.S. dollar/PRC exchange rate between the vesting/sale
date and (if later) when the sale proceeds can be converted into local currency, the sale proceeds that you receive may be more or less than the market value of the Shares on the vesting/sale date (which is the amount relevant to determining your
tax liability). You agree to bear the risk of any currency fluctuation between the date the Performance Share Units vest and the date of conversion of the proceeds into local currency. 
 You further agree to comply with any other requirements that may be imposed by the Company in the future to facilitate compliance with exchange control requirements in China. 

  
 Addendum-4

 Colombia 
 Exchange Control Information. Investments in assets located outside of Colombia (including Shares) are subject to registration with the Central Bank (Banco de la República) if the aggregate
value of such investments is US$500,000 or more (as of December 31 of the applicable calendar year). Further, upon the sale of any Shares that you have registered with the Central Bank, you must cancel the registration by March 31 of the
following year. You may be subject to fines if you fail to cancel such registration. 
 Czech Republic 

Exchange Control Information. The Czech National Bank may require you to fulfill certain notification duties in relation to the Performance Share
Units and the opening and maintenance of a foreign account. However, because exchange control regulations change frequently and without notice, you should consult your personal legal advisor prior to the vesting of the Performance Share Units and
the sale of Shares to ensure compliance with current regulations. It is your responsibility to comply with any applicable Czech exchange control laws. 
 Denmark 
 Stock Option Act. You acknowledge that you have received an Employer
Statement in Danish. 
 Exchange Control Information. If you establish an account holding Shares or an account holding cash outside
Denmark, you must report the account to the Danish Tax Administration. The form may be obtained from a local bank. Please note that these obligations are separate from and in addition to the obligations described below. 

Securities/Tax Reporting Information. If you hold Shares acquired under the Plan in a brokerage account with a broker or bank outside Denmark, you
are required to inform the Danish Tax Administration about the account. For this purpose, you must file a Form V (Erklaering V) with the Danish Tax Administration. Both you and the broker or bank must sign the Form V. By signing the
Form V, the broker or bank undertakes an obligation, without further request each year and not later than February 1 of the year following the calendar year to which the information relates, to forward information to the Danish Tax
Administration concerning the Shares in the account. In the event that the applicable broker or bank with which the account is held does not wish to, or, pursuant to the laws of the country in question, is not allowed to assume such obligation to
report, you acknowledge that you are solely responsible for providing certain details regarding the foreign brokerage or bank account and any Shares acquired at vesting and held in such account to the Danish Tax Administration as part of your annual
income tax return. By signing the Form V, you authorize the Danish Tax Administration to examine the account. A sample of the Form V can be found at the following website: www.skat.dk. 

In addition, if you open a brokerage account (or a deposit account with a U.S. bank), the brokerage account likely will be treated as a deposit account
because cash can be held in the account. Therefore, you likely must file a Form K (Erklaering K) with the Danish Tax Administration. The Form K must be signed both by you and by the applicable broker or bank where the account is held.
By signing the Form K, the broker/bank undertakes an obligation, without further request each year and not later than February 1 of the year following the calendar year to which the information relates, to forward information to the Danish
Tax Administration concerning the content of the account. In the event that the applicable financial institution (broker or bank) with which the account is held, does not wish to, or, pursuant to the laws of the country in question, is not allowed
to assume such obligation to report, you acknowledge that you are solely responsible for providing certain details regarding the foreign brokerage or bank account to the Danish Tax Administration as part of your annual income tax return. By signing
the Form K, you authorize the Danish Tax Administration to examine the account. A sample of the Form K can be found at the following website: www.skat.dk. 

  
 Addendum-5

 Ecuador 
 There are no country-specific provisions. 
 Egypt 

Exchange Control Information. If you transfer funds into Egypt in connection with the Performance Share Units, you are required to transfer the
funds through a registered bank in Egypt. 
 European Union Member States 

Retirement. The following provision supplements Section 6 of the Agreement: 
 Notwithstanding the foregoing, if the EU Employment Equality Directive has been implemented in your country of employment or residence or if the Company receives a legal opinion that there has been a
legal judgment and/or legal development in your jurisdiction that likely would result in the favorable Retirement treatment that applies to the Performance Share Units under the Plan being deemed unlawful and/or discriminatory, the provision above
regarding termination of employment due to Retirement shall not be applicable to you. 
 Finland 

There are no country specific provisions. 
 France 
 Language Acknowledgement 

En signant et renvoyant le présent document décrivant les termes et conditions de votre attribution, vous confirmez ainsi avoir lu et
compris les documents relatifs á cette attribution (le Plan et ce Contrat d’Attribution) qui vous ont été communiqués en langue anglaise. 
 By accepting your Performance Share Units, you confirm having read and understood the documents relating to this grant (the Plan and this Agreement) which were provided to you in English. 

Exchange Control Information. If you import or export cash (e.g., sales proceeds received under the Plan) with a value equal to or
exceeding €10,000 and do not use a financial institution to do so, you must submit a report to the customs and excise authorities.
 If you
hold Shares outside of France or maintain a foreign bank account, you are required to report such to the French tax authorities when filing your annual tax return. Failure to comply could trigger significant penalties. 

Germany 
 Exchange
Control Information. Cross-border payments in excess of €12,500 must be reported monthly to the German Federal Bank. In the event that you make or receive a payment in excess of this amount, you are responsible for obtaining the appropriate
form from the remitting bank and complying with applicable reporting requirements. 

  
 Addendum-6

 Greece 
 There are no country-specific provisions. 
 Hong Kong 

Securities Law Information. Warning: The Performance Share Units and any Shares issued at vesting do not constitute a public offering of
securities under Hong Kong law and are available only to employees of the Company or its subsidiaries. The Agreement, including this Addendum, the Plan and other incidental communication materials have not been prepared in accordance with and are
not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong, nor have the documents been reviewed by any regulatory authority in Hong Kong. The Performance Share
Units are intended only for the personal use of each eligible employee of the Employer, the Company or any subsidiary and may not be distributed to any other person. If you are in any doubt about any of the contents of the Agreement, including this
Addendum, or the Plan, or any other incidental communication materials, you should obtain independent professional advice. 
 Settlement
of Performance Share Units and Sale of Shares. Notwithstanding any terms or conditions of the Plan or the Agreement to the contrary, Performance Share Units will be settled in Shares only, not cash. In addition, notwithstanding any terms or
conditions of the Plan or the Agreement to the contrary, no Shares acquired under the Plan can be sold prior to six months from the Award Date. 

Nature of Scheme. The Company specifically intends that the Plan will not be an occupational retirement scheme for purposes of the Occupational
Retirement Schemes Ordinance (“ORSO”). 
 Hungary 
 There are no country-specific provisions. 
 India 

Exchange Control Information. You must repatriate all proceeds received from the sale of Shares and any cash dividends to India within a
reasonable time following the sale (i.e., within 90 days). You must maintain the foreign inward remittance certificate received from the bank where the foreign currency is deposited in the event that the Reserve Bank of India or the Company
or the Employer requests proof of repatriation. It is your responsibility to comply with applicable exchange control laws in India. 

Effective April 1, 2012, you are required to declare in your annual tax return (a) any foreign assets held by you or (b) any foreign bank
accounts for which you have signing authority. 
 Ireland 
 Director Notification Obligation. If you are a director, shadow director, or secretary of an Irish subsidiary, you are subject to certain notification requirements under the Companies Act, 1990.
Among these requirements is an obligation to notify the Irish subsidiary in writing within five business days of receiving or disposing of an interest (e.g., Performance Share Units, Shares) in the Company and the number and class of Shares or
rights to which the interest relates, or within five business days of becoming aware of the event giving rise to the notification requirement or within five days of becoming a director or secretary if such an interest exists at the time. This
disclosure requirement also applies to any rights or Shares acquired by your spouse or child(ren) (under the age of 18). 

Israel 
 Settlement of
Performance Share Units and Sale of Shares. Due to local regulatory requirements, upon the vesting of the Performance Share Units, you agree to the immediate sale of any Shares to be issued to you upon vesting and settlement of the Performance
Share Units. You further agree that the Company is authorized to instruct its designated broker to assist with the mandatory sale of such Shares 

  
 Addendum-7

 
(on your behalf pursuant to this authorization) and you expressly authorize the Company’s designated broker to complete the sale of such Shares. You acknowledge that the Company’s
designated broker is under no obligation to arrange for the sale of the Shares at any particular price. Upon the sale of the Shares, the Company agrees to pay you the cash proceeds from the sale of the Shares, less any brokerage fees or commissions
and subject to any obligation to satisfy Tax-Related Items. 
 Italy 

Data Privacy Notice. This section replaces Section 22 of the Agreement: 
 You understand that the Company and the Employer are the privacy representatives of the Company in Italy and may hold certain personal information about you, including, but not limited to, your name, home
address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any Shares or directorships held in the Company or any subsidiaries, details of all Performance Share Units or any other
entitlement to Shares awarded, canceled, vested, unvested or outstanding in your favor, and that the Company and the Employer will process said data and other data lawfully received from third parties (“Personal Data”) for the exclusive
purpose of managing and administering the Plan and complying with applicable laws, regulations and Community legislation. You also understand that providing the Company with Personal Data is mandatory for compliance with laws and is necessary for
the performance of the Plan and that your denial to provide Personal Data would make it impossible for the Company to perform its contractual obligations and may affect your ability to participate in the Plan. You understand that Personal Data will
not be publicized, but it may be accessible by the Employer as the privacy representative of the Company and within the Employer’s organization by its internal and external personnel in charge of processing, and by Morgan Stanley Smith Barney
or any other data processor appointed by the Company. The updated list of processors and of the subjects to which Data are communicated will remain available upon request from the Employer. Furthermore, Personal Data may be transferred to banks,
other financial institutions or brokers involved in the management and administration of the Plan. You understand that Personal Data may also be transferred to the independent registered public accounting firm engaged by the Company, and also to the
legitimate addressees under applicable laws. You further understand that the Company and its subsidiaries will transfer Personal Data amongst themselves as necessary for the purpose of implementation, administration and management of your
participation in the Plan, and that the Company and its subsidiaries may each further transfer Personal Data to third parties assisting the Company in the implementation, administration and management of the Plan, including any requisite transfer of
Personal Data to Morgan Stanley Smith Barney or other third party with whom you may elect to deposit any Shares acquired under the Plan or any proceeds from the sale of such Shares. Such recipients may receive, possess, use, retain and transfer
Personal Data in electronic or other form, for the purposes of implementing, administering and managing your participation in the Plan. You understand that these recipients may be acting as controllers, processors or persons in charge of processing,
as the case may be, according to applicable privacy laws, and that they may be located in or outside the European Economic Area, such as in the United States or elsewhere, in countries that do not provide an adequate level of data protection as
intended under Italian privacy law. 
 Should the Company exercise its discretion in suspending all necessary legal obligations connected with
the management and administration of the Plan, it will delete Personal Data as soon as it has accomplished all the necessary legal obligations connected with the management and administration of the Plan. 

You understand that Personal Data processing related to the purposes specified above shall take place under automated or non-automated conditions,
anonymously when possible, that comply with the purposes for which Personal Data is collected and with confidentiality and security provisions as set forth by applicable laws and regulations, with specific reference to Legislative Decree
no. 196/2003. 

  
 Addendum-8

 The processing activity, including communication, the transfer of Personal Data abroad, including outside of
the European Economic Area, as specified herein and pursuant to applicable laws and regulations, does not require your consent thereto as the processing is necessary to performance of law and contractual obligations related to implementation,
administration and management of the Plan. You understand that, pursuant to section 7 of the Legislative Decree no. 196/2003, you have the right at any moment to, including, but not limited to, obtain confirmation that Personal Data exists
or not, access, verify its contents, origin and accuracy, delete, update, integrate, correct, block or stop, for legitimate reason, the Personal Data processing. To exercise privacy rights, you should contact the Employer. Furthermore, you are aware
that Personal Data will not be used for direct marketing purposes. In addition, Personal Data provided can be reviewed and questions or complaints can be addressed by contacting your human resources department. 

Plan Document Acknowledgment. By accepting the Performance Share Units, you acknowledge that you have received a copy of the Plan, reviewed the
Plan, the Agreement and this Addendum in their entirety and fully understand and accept all provisions of the Plan, the Agreement and this Addendum. 
 In addition, you further acknowledge that you have read and specifically and expressly approve without limitation the following clauses in the Agreement: Section 9 (Responsibility for Taxes);
Section 13 (Acknowledgement of Nature of Plan and Performance Share Units); Section 14 (No Advice Regarding Grant); Section 15 (Right to Continued Employment); Section 17 (Deemed Acceptance); Section 19 (Severability and
Validity); Section 20 (Governing Law, Jurisdiction and Venue); Section 22 (Data Privacy, as replaced by the above provision in this Addendum); Section 23 (Electronic Delivery and Acceptance); Section 24 (Language);
Section 25 (Compliance with Laws and Regulations); Section 26 (Entire Agreement and No Oral Modification or Waiver); Section 27 (Addendum); and Section 28 (Imposition of Other Requirements). 

Additional Tax/Exchange Control Information. You are required to report in your annual tax return: (a) any transfers of cash or Shares to or
from Italy exceeding €10,000 or the equivalent amount in U.S. dollars; (b) any foreign investments or investments (including proceeds from the sale of Shares acquired under the Plan) held outside of Italy exceeding €10,000 or the
equivalent amount in U.S. dollars, if the investment may give rise to taxable income in Italy and (c) the amount of the transfers to and from abroad which have had an impact during the calendar year on your foreign investments or investments
held outside of Italy. Under certain circumstances, you may be exempt from requirement under (a) above if the transfer or investment is made through an authorized broker resident in Italy. 

Starting from 2011, a tax on the value of financial assets held outside of Italy by Italian residents has been introduced. The tax will apply at an
annual rate of 0.15% beginning in 2013. The taxable amount will be the fair market value of the financial assets, assessed at the end of the calendar year. For the purposes of the market value assessment, the documentation issued by the Plan broker
may be used. 
 Japan 
 Offshore Assets Reporting Information. You will be required to report details of any assets (including any Shares acquired under the Plan) held outside of Japan as of December 31st of each
year, to the extent such assets have a total net fair market value exceeding ¥50,000,000. Such report will be due by March 15th of the following year. You should consult with your personal tax advisor as to whether the reporting obligation
applies to you and whether you will be required to report details of any outstanding Performance Share Units or Shares held by you in the report. 
 Korea 
 Exchange Control Information. Korean residents who realize US$500,000 or
more from the sale of Shares or receipt of dividends in a single transaction are required to repatriate the proceeds to Korea within 18 months of receipt. 

  
 Addendum-9

 Kuwait 
 There are no country-specific provisions. 
 Luxembourg 

Exchange Control Information. You are required to report any inward remittances of funds to the Banque Central de Luxembourg and/or the
Service Central de La Statistique et des Études Économiques within 15 working days following the month during which the transaction occurred. If a Luxembourg financial institution is involved in the transaction, it generally
will fulfill the reporting obligation on your behalf. 
 Mexico 
 Labor Law Policy and Acknowledgment. By accepting this Award, you expressly recognize that the Company, with offices at 345 Park Avenue, New York, New York 10154, U.S.A., is solely responsible for
the administration of the Plan and that your participation in the Plan and acquisition of shares does not constitute an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis and your
sole employer is Bristol-Myers Squibb Company in Mexico (“BMS-Mexico”), not the Company in the United States. Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participation in the Plan
do not establish any rights between you and your employer, BMS-Mexico, and do not form part of the employment conditions and/or benefits provided by BMS-Mexico and any modification of the Plan or its termination shall not constitute a change or
impairment of the terms and conditions of your employment. 
 You further understand that your participation in the Plan is as a result of a
unilateral and discretionary decision of the Company; therefore, the Company reserves the absolute right to amend and/or discontinue your participation at any time without any liability to you. 

Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against the Company for any compensation or
damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to the Company, its subsidiaries, affiliates, branches, representation offices, its shareholders, officers, agents
or legal representatives with respect to any claim that may arise. 
 Política Laboral y
Reconocimiento/Aceptación. Aceptando este Premio1, el participante reconoce que la Compañía, with offices at 345 Park Avenue, New York, New York 10154, U.S.A., es el único responsable de la
administración del Plan y que la participación del Participante en el mismo y la adquisicion de acciones no constituye de ninguna manera una relación laboral entre el Participante y la Compañía, toda vez que la
participación del participante en el Plan deriva únicamente de una relación comercial con la Compañía, reconociendo expresamente que el único empleador del participante lo es Bristol-Myers Squibb Company en
Mexico (“BMS-Mexico”), no es la Compañía en los Estados Unidos. Derivado de lo anterior, el participante expresamente reconoce que el Plan y los beneficios que pudieran derivar del mismo no establecen ningún derecho
entre el participante y su empleador, BMS-México, y no forman parte de las condiciones laborales y/o prestaciones otorgadas por BMS-México, y expresamente el participante reconoce que cualquier modificación el Plan o la
terminación del mismo de manera alguna podrá ser interpretada como una modificación de los condiciones de trabajo del participante. 

 

	1	El término “Premio” se refiere a la palabra “Award.” 

  
 Addendum-10

 Asimismo, el participante entiende que su participación en el Plan es resultado de la
decisión unilateral y discrecional de la Compañía, por lo tanto, la Compañía. Se reserva el derecho absoluto para modificar y/o terminar la participación del participante en cualquier momento, sin ninguna
responsabilidad para el participante. 
 Finalmente, el participante manifiesta que no se reserva ninguna acción o derecho que
origine una demanda en contra de la Compañía, por cualquier compensación o daño en relación con cualquier disposición del Plan o de los beneficios derivados del mismo, y en consecuencia el participante
otorga un amplio y total finiquito a la Compañía, sus entidades relacionadas, afiliadas, sucursales, oficinas de representación, sus accionistas, directores, agentes y representantes legales con respecto a cualquier demanda que
pudiera surgir. 
 Netherlands 
 Insider-Trading Notification. You should be aware of the Dutch insider-trading rules, which may impact the sale of Shares issued to you at settlement of the Performance Share Units. In particular,
you may be prohibited from effectuating certain transactions involving Shares if you have inside information about the Company. 
 Under
Article 5:56 of the Dutch Financial Supervision Act, anyone who has “inside information” related to an issuing company is prohibited from effectuating a transaction in securities in or from the Netherlands. “Inside
information” is defined as knowledge of specific information concerning the issuing company to which the securities relate or the trade in securities issued by such company, which has not been made public and which, if published, would
reasonably be expected to affect the share price, regardless of the development of the price. The insider could be any employee of a subsidiary in the Netherlands who has inside information as described herein. 

Given the broad scope of the definition of inside information, certain employees working at a subsidiary in the Netherlands may have inside information
and, thus, would be prohibited from effectuating a transaction in securities in the Netherlands at a time when they have such inside information. 
 By accepting the Performance Share Units and the underlying Shares, you acknowledge having read and understood the notification above and acknowledge that it is your responsibility to comply with the
Dutch insider trading rules, as discussed herein. 
 If you are uncertain whether the insider-trading rules apply to you, you should consult
your personal legal advisor. 
 Norway 
 There are no country-specific provisions. 
 Peru 

Securities Law Information. The grant of Performance Share Units is considered a private offering in Peru; therefore, it is not subject to
registration. 
 Poland 
 Exchange Control Information. Polish residents holding foreign securities (including Shares) and maintaining accounts abroad must report information to the National Bank of Poland. Specifically, if
the aggregate value of shares and cash held in such foreign accounts exceeds PLN 7 million, Polish residents must file reports on the transactions and balances of the accounts on a quarterly basis on special forms

  
 Addendum-11

 
that are available on the website of the National Bank of Poland. In addition, Polish residents are required to transfer funds (i.e., in connection with the sale of Shares) through a bank
account in Poland if the transferred amount in any single transaction exceeds a specified threshold (currently €15,000). If you are a Polish resident, you must also store all documents connected with any foreign exchange transactions you engage
in for a period of five years, as measured from the end of the year in which such transaction occurred. You should consult with your personal legal advisor to determine what you must do to fulfill any applicable reporting duties. 

Portugal 
 Language
Consent. You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accepted and agreed with the terms and conditions established in the Plan and the Agreement. 

Conhecimento da Lingua. Você expressamente declara ter pleno conhecimento do idioma inglês e ter lido, entendido e totalmente aceito e
concordou com os termos e condições estabelecidas no plano e no acordo. 
 Exchange Control Information. If you acquire
Shares under the Plan and do not hold the shares with a Portuguese financial intermediary, you may need to file a report with the Portuguese Central Bank. If the shares are held by a Portuguese financial intermediary, it will file the report for
you. 
 Puerto Rico 
 There are no country-specific provisions. 
 Romania 

Exchange Control Information. If you deposit the proceeds from the sale of your Shares in a bank account in Romania, you may have to provide the
Romanian bank through which the operations are effected with appropriate documentation regarding the receipt of the income. You should consult with a personal legal advisor to determine whether you will be required to submit such documentation to
the Romanian bank. 
 Russia 
 Exchange Control Information. You acknowledge that you must repatriate the proceeds from the sale of Shares and any dividends/Dividend Equivalents received in relation to the Performance Share
Units within a reasonably short time of receipt. Such amounts must be initially credited to you through a foreign currency account opened in your name at an authorized bank in Russia. After the funds are initially received in Russia, they may be
further remitted to foreign banks subject to the following limitations: (i) the foreign account may be opened only for individuals; (ii) the foreign account may not be used for business activities; and (iii) you must give notice to
the Russian tax authorities about the opening/closing of each foreign account within one month of the account opening/closing. 
 Securities
Law Information. These materials do not constitute advertising or an offering of securities in Russia nor do they constitute placement of the Shares in Russia. The issuance of Shares pursuant to the Performance Share Units described herein has
not and will not be registered in Russia and hence, the Shares described herein may not be admitted or used for offering, placement or public circulation in Russia. 

  
 Addendum-12

 U.S. Transaction. Any Shares issued pursuant to the Performance Share Units shall be delivered to you
through a brokerage account in the U.S. You may hold Shares in your brokerage account in the U.S.; however, in no event will shares issued to you and/or share certificates or other instruments be delivered to you in Russia. You are not permitted to
make any public advertising or announcements regarding the Performance Share Units or Shares in Russia, or promote these shares to other Russian legal entities or individuals, and you are not permitted to sell or otherwise dispose of Shares directly
to other Russian legal entities or individuals. You are permitted to sell Shares only on the New York Stock Exchange and only through a U.S. broker. 
 Data Privacy Consent. This section replaces Section 22 of the Agreement: 
 You hereby
explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement by and among, as applicable, your Employer, the Company and its subsidiaries for the
exclusive purpose of implementing, administering and managing your participation in the Plan. 
 You understand that the Company, any subsidiary
and/or your Employer may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title,
any shares of stock or directorships held in the Company, details of all Performance Share Units or any other entitlement to shares awarded, canceled, vested, unvested or outstanding in your favor, for the purpose of implementing, administering and
managing the Plan (“Data”). 
 You understand that Data may be transferred to Morgan Stanley Smith Barney, or such other stock plan
service provider as may be selected by the Company in the future, which assists in the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and
that the recipient’s country (e.g. the United States) may have different data privacy laws and protections than your country. You understand that if you reside outside the United States, you may request a list with the names and addresses of
any potential recipients of the Data by contacting the International Compensation and Benefits Group. You authorize the Company, Morgan Stanley Smith Barney and other possible recipients which may assist the Company (presently or in the future) with
implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan, including any
requisite transfer of such Data as may be required to a broker, escrow agent or other third party with whom the Shares received upon vesting of the Performance Share Units may be deposited. You understand that Data will be held only as long as is
necessary to implement, administer and manage your participation in the Plan. You understand that if you reside outside the United States, you may, at any time, view Data, request additional information about the storage and processing of Data,
require any necessary amendments to Data or refuse or withdraw the consents herein, in any case and without cost, by contacting in writing the International Compensation and Benefits Group. Further, you understand that you are providing the consents
herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service and career with the Employer will not be adversely affected; the only adverse consequence of refusing or
withdrawing your consent is that the Company would not be able to grant you Performance Share Units or other equity awards or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your
ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact the International Compensation and Benefits Group. 

Labor Law Information. You acknowledge that if you continue to hold Shares acquired under the Plan after an involuntary termination of your
employment, you will not be eligible to receive unemployment benefits in Russia. 

  
 Addendum-13

 Saudi Arabia 
 Securities Law Information. This document may not be distributed in the Kingdom except to such persons as are permitted under the Offers of Securities Regulations issued by the Capital Market
Authority. 
 The Capital Market Authority does not make any representation as to the accuracy or completeness of this document, and expressly
disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information
relating to the securities. If you do not understand the contents of this document you should consult an authorized financial advisor. 
 Singapore 
 Securities Law Information. The grant of Performance Share Units is
being made in reliance of section 273(1)(f) of the Securities and Futures Act (Chap. 289) (“SFA”) for which it is exempt from the prospectus and registration requirements under the SFA. The Plan has not been lodged or registered as a
prospectus with the Monetary Authority of Singapore. You should note that the Performance Share Units are subject to section 257 of the SFA and you will not be able to make (i) any subsequent sale of the Shares in Singapore or (ii) any
offer of such subsequent sale of the Shares subject to the Performance Share Units in Singapore, unless such sale or offer is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the SFA
(Chapter 289, 2006 Ed.). 
 Director Notification Requirement. If you are a director, associate director or shadow director of a
Singapore company, you are subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore company in writing when you receive an interest (e.g., Performance Share
Units, Shares) in the Company or any related companies. In addition, you must notify the Singapore company when you sell shares of the Company or any related company (including when you sell Shares acquired pursuant to your Performance Share Units).
These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of your interests in the Company or any related company within two
business days of becoming a director. 
 Insider Trading Notification. You should be aware of the Singapore insider trading rules, which
may impact the acquisition or disposal of shares or rights to Shares under the Plan. Under the Singapore insider trading rules, you are prohibited from acquiring or selling Shares or rights to Shares (e.g., Performance Share Units under the Plan)
when you are in possession of information which is not generally available and which you know or should know will have a material effect on the price of Shares once such information is generally available. 

South Africa 

Exchange Control Information. You are solely responsible for complying with applicable South African exchange control regulations. Because the
exchange control regulations change frequently and without notice, you should consult your legal advisor prior to the acquisition or sale of Shares under the Plan to ensure compliance with current regulations. As noted, it is your responsibility to
comply with South African exchange control laws, and neither the Company nor the Employer will be liable for any fines or penalties resulting from failure to comply with applicable laws. 

  
 Addendum-14

 Spain 
 Exchange Control Information. To participate in the Plan, you must comply with exchange control regulations in Spain. When receiving foreign currency payments exceeding €50,000 derived from
the ownership of Shares issued pursuant to the Performance Share Units (i.e., dividends, Dividend Equivalents or sale proceeds), you must inform the financial institution receiving the payment of the basis upon which such payment is made. You
will need to provide the institution with the following information: (i) your name, address, and fiscal identification number; (ii) the name and corporate domicile of the Company; (iii) the amount of the payment and the currency used;
(iv) the country of origin; (v) the reasons for the payment; and (vi) further information that may be required. 
 If you acquire
Shares issued pursuant to the Performance Share Units and wish to import the ownership title of such shares (i.e., share certificates) into Spain, you must declare the importation of such securities to the Spanish Direccion General de
Política Comercial y de Inversiones Extranjeras (the “DGPCIE”). Generally, the declaration must be made in January for Shares acquired or sold during (or owned as of December 31 of) the prior year; however, if the value of
shares acquired or sold exceeds €1,502,530 (or you hold 10% or more of the share capital of the Company or such other amount that would entitle you to join the Company’s board of directors), the declaration must be filed within one month
of the acquisition or sale, as applicable. In addition, you also must file a declaration of ownership of foreign securities with the Directorate of Foreign Transactions each January. 
 Further, effective January 1, 2013, to the extent that you hold assets (e.g., cash or Shares held in a bank or brokerage account) or rights (e.g., the Performance Share Units) outside of Spain with a
value in excess of €20,000 (on a per-asset basis) as of December 31 each year, you will be required to report information on such rights and assets on your tax return for such year. 
 Labor Law Acknowledgment. This provision supplements Sections 6 and 13 of the Agreement: 
 By accepting the Performance Share Units, you consent to participation in the Plan and acknowledge that you have received a copy of the Plan document. 

You understand and agree that, as a condition of the grant of the Performance Share Units, except as provided for in Section 2 of the Agreement,
your termination of employment for any reason (including for the reasons listed below) will automatically result in the forfeiture of any Performance Share Units that have not vested on the date of your termination. 

In particular, you understand and agree that, unless otherwise provided in the Agreement, the Performance Share Units will be forfeited without
entitlement to the underlying Shares or to any amount as indemnification in the event of a termination of your employment prior to vesting by reason of, including, but not limited to: resignation, disciplinary dismissal adjudged to be with cause,
disciplinary dismissal adjudged or recognized to be without cause, individual or collective layoff on objective grounds, whether adjudged to be with cause or adjudged or recognized to be without cause, material modification of the terms of
employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer, and under Article 10.3 of Royal
Decree 1382/1985. 
 Furthermore, you understand that the Company has unilaterally, gratuitously and discretionally decided to grant
Performance Share Units under the Plan to individuals who may be employees of the Company or a subsidiary. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or
otherwise bind the Company or any subsidiary on an ongoing basis, other than as expressly set forth in the Agreement. Consequently, you understand that the Performance Share Units are granted on the assumption and condition that the Performance
Share Units and the Shares underlying the Performance Share Units shall not become a part of any employment or service contract (either with the Company, the Employer or any subsidiary) and shall not be considered a mandatory benefit, salary for any
purposes (including severance compensation) or any other right whatsoever. In addition, you understand that the Performance Share Units would not be granted to you but for the assumptions and conditions referred to above; thus, you acknowledge and
freely accept that, should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any Award of Performance Share Units shall be null and void. 

  
 Addendum-15

 Securities Law Information. The Performance Share Units and the Shares described in the Agreement and
this Addendum do not qualify under Spanish regulations as securities. No “offer of securities to the public,” as defined under Spanish law, has taken place or will take place in the Spanish territory. The Agreement (including this
Addendum) has not been nor will it be registered with the Comisión Nacional del Mercado de Valores, and does not constitute a public offering prospectus. 
 Sweden 
 There are no country-specific provisions. 

Switzerland 

Securities Law Information. The Performance Share Units offered are considered a private offering in Switzerland; therefore, they are not subject
to registration in Switzerland. 
 Taiwan 
 Exchange Control Information. You may remit foreign currency (including proceeds from the sale of Shares) into or out of Taiwan up to US$5,000,000 per year without special permission. If the
transaction amount is TWD500,000 or more in a single transaction, you must submit a Foreign Exchange Transaction Form to the remitting bank and provide supporting documentation to the satisfaction of the remitting bank. 

Thailand 
 Exchange
Control Information. If the proceeds from the sale of Shares or the receipt of dividends are equal to or greater than US$50,000 or more in a single transaction, you must repatriate the proceeds to Thailand immediately upon receipt and convert
the funds to Thai Baht or deposit the proceeds in a foreign currency deposit account maintained by a bank in Thailand within 360 days of remitting the proceeds to Thailand. In addition you must report the inward remittance to the Bank of
Thailand on a foreign exchange transaction form. If you fail to comply with these obligations, you may be subject to penalties assessed by the Bank of Thailand. Because exchange control regulations change frequently and without notice, you should
consult your personal advisor before selling Shares to ensure compliance with current regulations. You are responsible for ensuring compliance with all exchange control laws in Thailand, and neither the Company nor any of its subsidiaries will be
liable for any fines or penalties resulting from your failure to comply with applicable laws. 
 Tunisia 

Securities Law Information. All proceeds from the sale of Shares must be repatriated to Tunisia. You should consult your personal advisor before
taking action with respect to remittance of proceeds into Tunisia. You are responsible for ensuring compliance with all exchange control laws in Tunisia. In addition, if you hold assets abroad in excess of a certain amount, you must report the
assets to the Central Bank of Tunisia. 
 Turkey 
 Securities Law Information. Under Turkish law, you are not permitted to sell Shares acquired under the Plan in Turkey. The Shares are currently traded on the New York Stock Exchange, which is
located outside of Turkey, under the ticker symbol “BMY” and the Shares may be sold through this exchange. 

  
 Addendum-16

 United Arab Emirates 
 Securities Law Information. The Plan is only being offered to qualified employees and is in the nature of providing equity incentives to employees of the Company or its subsidiary or affiliate in
the UAE. Any documents related to the Plan, including the Plan, Plan prospectus and other grant documents (“Plan Documents”), are intended for distribution only to such employees and must not be delivered to, or relied on by, any other
person. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of the Plan Documents, you should consult an authorized financial adviser. 

The Emirates Securities and Commodities Authority has no responsibility for reviewing or verifying any Plan Documents nor taken steps to verify the
information set out in them, and thus, are not responsible for such documents. 
 United Kingdom 

Responsibility for Taxes. This provision supplements Section 9 of the Agreement: 
 You agree that, if you do not pay or the Employer or the Company does not withhold from you the full amount of Tax-Related Items that you owe at vesting and settlement of the Performance Share Units, or
the release or assignment of the Performance Share Units for consideration, or the receipt of any other benefit in connection with the Performance Share Units (the “Taxable Event”) within 90 days after the Taxable Event, or such other
period specified in Section 222(1)(c) of the U.K. Income Tax (Earnings and Pensions) Act 2003, then the amount of income tax that should have been withheld shall constitute a loan owed by you to the Employer, effective 90 days after the Taxable
Event. You agree that the loan will bear interest at Her Majesty’s Revenue & Customs’ (“HMRC”) official rate and will be immediately due and repayable by you, and the Company and/or the Employer may recover it at any
time thereafter by withholding the funds from salary, bonus or any other funds due to you by the Employer, by withholding in Shares issued upon vesting of your Performance Share Units or from the cash proceeds from the sale of Shares or by demanding
cash or a cheque from you. You also authorize the Company to delay the issuance of any Shares unless and until the loan is repaid in full. 

Notwithstanding the foregoing, if you are an officer or executive director (as within the meaning of Section 13(k) of the U.S. Securities Exchange
Act of 1934, as amended), the terms of the immediately foregoing provision will not apply. In the event that you are an officer or executive director and the income tax that is due is not collected from or paid by you within 90 days of the Taxable
Event, the amount of any uncollected income tax may constitute a benefit to you on which additional income tax and national insurance contributions may be payable. You will be responsible for reporting and paying any income tax due on this
additional benefit directly to the HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as appropriate) for the value of any employee national insurance contributions due on this additional benefit. 

Venezuela 
 Securities
Law Information. The Performance Share Units granted under the Plan and the Shares issued under the Plan are offered as a personal, private, exclusive transaction and are not subject to Venezuelan securities regulations. 

Exchange Control Information. Exchange control restrictions may limit the ability to remit funds out of Venezuela in order to receive Shares upon
vesting of the Performance Share Units, or remit funds into Venezuela following the sale of Shares acquired upon vesting of the Performance Share Units. The Company reserves the right to restrict settlement of the Performance Share Units or to amend
or cancel the Performance Share Units at any time in order to comply with applicable exchange control laws in 

  
 Addendum-17

 
Venezuela. Any Shares acquired under the Plan are intended to be an investment rather than for the resale and conversion of the shares into foreign currency. You are responsible for complying
with exchange control laws in Venezuela and neither the Company nor the Employer will be liable for any fines or penalties resulting from your failure to comply with applicable laws. Because exchange control laws and regulations change frequently
and without notice, you should consult with you personal legal advisor before accepting the Performance Share Units and before selling any Shares acquired upon vesting of the Performance Share Units to ensure compliance with current regulations.

  
 Addendum-18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]